CA2103059A1 - Method for making humanized antibodies - Google Patents

Method for making humanized antibodies

Info

Publication number
CA2103059A1
CA2103059A1 CA 2103059 CA2103059A CA2103059A1 CA 2103059 A1 CA2103059 A1 CA 2103059A1 CA 2103059 CA2103059 CA 2103059 CA 2103059 A CA2103059 A CA 2103059A CA 2103059 A1 CA2103059 A1 CA 2103059A1
Authority
CA
Grant status
Application
Patent type
Prior art keywords
method
humanized antibodies
making humanized
provided
making
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA 2103059
Other languages
French (fr)
Other versions
CA2103059C (en )
Inventor
Paul J. Carter
Leonard G. Presta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation

Links

Classifications

    • GPHYSICS
    • G06COMPUTING; CALCULATING; COUNTING
    • G06FELECTRIC DIGITAL DATA PROCESSING
    • G06F15/00Digital computers in general; Data processing equipment in general
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/461Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54F(ab')2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Abstract

Variant immunoglobulins, particularly humanized antibody polypeptides are provided, along with methods for their preparation and use. Consensus immunoglobulin sequences and structural models are also provided.
CA 2103059 1991-06-14 1992-06-15 Method for making humanized antibodies Expired - Lifetime CA2103059C (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US71527291 true 1991-06-14 1991-06-14
US07/715,272 1991-06-14
PCT/US1992/005126 WO1992022653A1 (en) 1991-06-14 1992-06-15 Method for making humanized antibodies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA 2481259 CA2481259A1 (en) 1991-06-14 1992-06-15 Method for making humanized antibodies

Publications (2)

Publication Number Publication Date
CA2103059A1 true true CA2103059A1 (en) 1992-12-15
CA2103059C CA2103059C (en) 2005-03-22

Family

ID=24873346

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2103059 Expired - Lifetime CA2103059C (en) 1991-06-14 1992-06-15 Method for making humanized antibodies

Country Status (10)

Country Link
US (4) US6407213B1 (en)
EP (3) EP1400536A1 (en)
JP (4) JP4124480B2 (en)
CA (1) CA2103059C (en)
DE (3) DE69233254T2 (en)
DK (1) DK0590058T3 (en)
ES (1) ES2206447T3 (en)
LU (1) LU91067I2 (en)
NL (1) NL300145I1 (en)
WO (1) WO1992022653A1 (en)

Families Citing this family (1297)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994025067A1 (en) * 1993-05-04 1994-11-10 Cytel Corporation Antibodies to p-selectin and their uses
US6054561A (en) * 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US5571714A (en) * 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US20040049014A1 (en) * 1988-12-28 2004-03-11 Protein Design Labs, Inc. Humanized immunoglobulins
GB9020282D0 (en) * 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
US5811267A (en) * 1990-10-29 1998-09-22 Chiron Corporation Isolated nucleic acid molecules encoding antigen binding sites of antibody molecules specific for cancer antigens
US5948647A (en) * 1990-10-29 1999-09-07 Chiron Corporation Nucleic acids encoding antigen-binding sites specific for cancer antigens
US5849877A (en) * 1990-10-29 1998-12-15 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
LU91067I2 (en) * 1991-06-14 2004-04-02 Genentech Inc Trastuzumab and its variants and derivatives chemical immuno including immotoxines
GB9115364D0 (en) * 1991-07-16 1991-08-28 Wellcome Found Antibody
US6685939B2 (en) 1991-08-14 2004-02-03 Genentech, Inc. Method of preventing the onset of allergic disorders
US6329509B1 (en) * 1991-08-14 2001-12-11 Genentech, Inc. Anti-IgE antibodies
US5869619A (en) * 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
GB9206422D0 (en) * 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
EP0578515A3 (en) * 1992-05-26 1995-05-10 Squibb Bristol Myers Co Humanized monoclonal antibodies.
EP0656789B1 (en) * 1992-08-21 1997-12-17 Genentech, Inc. Method for treating a lfa-1-mediated disorder
US5958708A (en) * 1992-09-25 1999-09-28 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US6066718A (en) * 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US20040067157A1 (en) * 1993-07-22 2004-04-08 Clearant, Inc. Methods for sterilizing biological materials
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US5708142A (en) 1994-05-27 1998-01-13 Genentech, Inc. Tumor necrosis factor receptor-associated factors
US5712249A (en) * 1994-09-08 1998-01-27 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
US5874540A (en) * 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
US7803904B2 (en) * 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5573762A (en) * 1995-04-24 1996-11-12 Genentech, Inc. Use of leukemia inhibitory factor specific antibodies and endothelin antagonists for treatment of cardiac hypertrophy
US20030224001A1 (en) * 1998-03-19 2003-12-04 Goldstein Neil I. Antibody and antibody fragments for inhibiting the growth of tumors
US20070065436A1 (en) * 2001-01-31 2007-03-22 Biogen Idec Inc. Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
CA2222231A1 (en) * 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
ES2435462T3 (en) 1995-07-27 2013-12-19 Genentech, Inc. Isotonic lyophilized protein formulation stable
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9601081D0 (en) * 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
WO1997046589A3 (en) 1996-06-07 2002-09-19 Neorx Corp Humanized antibodies that bind to the same antigen as bound by antibody nr-lu-13, and their use in pretargeting methods
JP3819436B2 (en) * 1996-07-11 2006-09-06 タカラバイオ株式会社 Site-directed mutagenesis method
US7129061B1 (en) * 1996-08-07 2006-10-31 Biogen Idec Ma Inc. Tumor necrosis factor related ligand
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US7371376B1 (en) * 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
US7083786B2 (en) 1997-04-03 2006-08-01 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US7365166B2 (en) 1997-04-07 2008-04-29 Genentech, Inc. Anti-VEGF antibodies
DE122007000021I1 (en) * 1997-04-07 2007-05-24 Genentech Inc Anti-VEFG Antibodies
EP1007630B1 (en) * 1997-04-30 2006-04-19 Hans Klingemann Natural killer cell lines and methods of use
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
US7951917B1 (en) 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US7276488B2 (en) 1997-06-04 2007-10-02 Oxford Biomedica (Uk) Limited Vector system
DK1012259T3 (en) 1997-06-04 2010-01-18 Oxford Biomedica Ltd Tumor-directed vector
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6172213B1 (en) * 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US20030082541A1 (en) * 1997-09-17 2003-05-01 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20020192659A1 (en) * 1997-09-17 2002-12-19 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2648046A1 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
EP2275549A1 (en) 2000-06-23 2011-01-19 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US6387657B1 (en) 1997-10-29 2002-05-14 Genentech, Inc. WISP polypeptides and nucleic acids encoding same
EP1039931B1 (en) * 1997-12-01 2005-04-27 Fang Fang Multivalent recombinant antibodies for treating hrv infections
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6617171B2 (en) * 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
WO1999047677A3 (en) 1998-03-17 1999-11-11 Genentech Inc Polypeptides homologous to vegf and bmp1
US7244826B1 (en) 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
EP1308456B1 (en) * 1998-05-06 2007-08-22 Genentech, Inc. Antibody purification by ion exchange chromatography
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
US7387772B1 (en) * 1999-06-22 2008-06-17 Immunimedics, Inc. Chimeric, human and humanized anti-CSAP monoclonal antibodies
GB9815909D0 (en) * 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
EP1150688A4 (en) * 1998-10-19 2004-06-16 Yeda Res & Dev Treatment of systemic lupus erythematosus by down-regulating the autoimmune response to autoantigens
DE69938054T2 (en) 1998-11-18 2009-02-12 Genentech, Inc., South San Francisco antibodies to parent with higher binding affinities compared antibody variants
CN1423660A (en) 1999-11-18 2003-06-11 牛津生物医学(英国)有限公司 Antibodies
EP1151012A4 (en) * 1998-11-19 2003-01-08 Smithkline Beecham Corp Rhamm antagonist antibodies
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US6599710B1 (en) 1999-03-10 2003-07-29 The General Hospital Corporation Treatment of autoimmune disease
ES2307505T3 (en) * 1999-04-06 2008-12-01 Genentech, Inc. Utilization erbB receptor ligands in the treatment of diabetes.
RU2294761C2 (en) * 1999-05-14 2007-03-10 Имклон Систимс Инкопэритид Method for treating resistant human tumors with epidermis growth factor receptors antagonists
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
US20030086924A1 (en) * 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
EP1191944A2 (en) 1999-06-25 2002-04-03 Genentech, Inc. METHODS OF TREATMENT USING ANTI-ErbB ANTIBODY-MAYTANSINOID CONJUGATES
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US20040013667A1 (en) * 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US20020068066A1 (en) * 1999-08-20 2002-06-06 Wenyuan Shi Method for the treatment and prevention of dental caries
DE60042693D1 (en) * 1999-08-27 2009-09-17 Genentech Inc Dosage for treatment with anti erbb2 antibodies
USRE43899E1 (en) 1999-10-01 2013-01-01 Immunogen Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US7947496B2 (en) 1999-10-08 2011-05-24 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US6346249B1 (en) * 1999-10-22 2002-02-12 Ludwig Institute For Cancer Research Methods for reducing the effects of cancers that express A33 antigen using A33 antigen specific immunoglobulin products
EP1372724A2 (en) 2001-01-31 2004-01-02 Idec Pharmaceuticals Corporation Use of immunoregulatory antibodies in the treatment of neoplastic disorders
JP2005503999A (en) 2001-01-31 2005-02-10 アイデック ファーマスーティカルズ コーポレイション Use of cd23 antagonists for the treatment of neoplastic diseases
US20020159996A1 (en) 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20060228364A1 (en) * 1999-12-24 2006-10-12 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US6686188B2 (en) 2000-05-26 2004-02-03 Amersham Plc Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
US6632979B2 (en) 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US6663863B2 (en) 2000-03-17 2003-12-16 Millennium Pharmaceuticals, Inc. Method of inhibiting stenosis and restenosis
US20010046496A1 (en) * 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
US20030158382A1 (en) 2000-04-21 2003-08-21 Nobutaka Wakamiya Novel collectins
EP1286692A4 (en) * 2000-04-25 2004-11-17 Idec Pharma Corp Intrathecal administration of rituximab for treatment of central nervous system lymphomas
EP1280923A2 (en) * 2000-04-28 2003-02-05 Millennium Pharmaceuticals, Inc. 14094, a human trypsin family member and uses thereof
US6656700B2 (en) 2000-05-26 2003-12-02 Amersham Plc Isoforms of human pregnancy-associated protein-E
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
CA2411102A1 (en) 2000-06-20 2001-12-27 Idec Pharmaceutical Corporation Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
WO2002011677A3 (en) * 2000-08-09 2002-05-02 Imclone Systems Inc Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
US6984494B2 (en) 2000-08-15 2006-01-10 Genentech, Inc. Analytical method
US20030035798A1 (en) * 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
DE60140457D1 (en) * 2000-09-01 2009-12-24 Blood Res Center Modified, stabilized in the desired conformation polypeptides and methods for their preparation
US20020119148A1 (en) * 2000-09-01 2002-08-29 Gerritsen Mary E. ErbB4 antagonists
US20030017491A1 (en) * 2000-09-14 2003-01-23 Zuo-Rong Shi Chromogenic in situ hybridization methods, kits, and compositions
WO2002046208A3 (en) * 2000-11-01 2002-08-08 Elusys Therapeutics Inc Method of producing biospecific molecules by protein trans-splicing
US20040018194A1 (en) * 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6979556B2 (en) * 2000-12-14 2005-12-27 Genentech, Inc. Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes
US20030049800A1 (en) * 2000-12-15 2003-03-13 Saravis Calvin A. Compositions and methods for producing antibodies to low molecular weight analytes
US7794713B2 (en) 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
US7132510B2 (en) * 2000-12-29 2006-11-07 Bio-Technology General (Israel) Ltd. Specific human antibodies for selective cancer therapy
US20040001822A1 (en) * 2000-12-29 2004-01-01 Avigdor Levanon Y1-isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20040001839A1 (en) * 2000-12-29 2004-01-01 Avigdor Levanon Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20040002450A1 (en) * 2000-12-29 2004-01-01 Janette Lazarovits Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20030211107A1 (en) * 2002-01-31 2003-11-13 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20030103971A1 (en) * 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
ES2398099T3 (en) * 2001-02-19 2013-03-13 Merck Patent Gmbh Modified anti-EGFR antibodies with reduced immunogenicity
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
WO2002072635A3 (en) * 2001-03-13 2002-11-07 Univ London Specific binding members
US20080008704A1 (en) * 2001-03-16 2008-01-10 Mark Rubin Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
EP1372717A2 (en) 2001-03-23 2004-01-02 Aphton Corporation Combination treatment of pancreatic cancer
ES2366775T3 (en) 2001-04-24 2011-10-25 Merck Patent Gmbh USING polytherapy antiangiogenic agents and TNF (alpha).
US20090191232A1 (en) 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
US6972324B2 (en) 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
US7132401B2 (en) 2001-05-22 2006-11-07 Merck & Co., Inc. Beta-secretase substrates and uses thereof
KR101004353B1 (en) 2001-05-30 2010-12-28 제넨테크, 인크. Anti-ngf antibodies for the treatment of various disorders
CA2817619A1 (en) * 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
WO2002100899A3 (en) 2001-06-13 2003-12-18 Osteopep Pharma Gmbh Medicament for treating tumours and their metastases using a binding molecule against bone-sialoprotein
DE50213368D1 (en) * 2001-06-13 2009-04-30 Immundiagnostik Ag Determination of bone-sialoprotein in body fluids for oncology clear question
EP2000482A1 (en) 2001-06-20 2008-12-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CA2450793A1 (en) 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
US7393656B2 (en) 2001-07-10 2008-07-01 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for risk stratification
EP1539233B1 (en) * 2001-07-12 2011-04-27 FOOTE, Jefferson Super humanized antibodies
CA2454358A1 (en) 2001-07-19 2003-07-31 Perlan Therapeutics, Inc. Multimeric proteins and methods of making and using same
US20040078837A1 (en) * 2001-08-02 2004-04-22 Shannon Mark E. Four human zinc-finger-containing proteins: MDZ3, MDZ4, MDZ7 and MDZ12
US7662374B2 (en) * 2001-08-03 2010-02-16 The Trustees Of The University Of Pennsylvania Monoclonal antibodies to activated erbB family members and methods of use thereof
US20030077739A1 (en) * 2001-08-27 2003-04-24 Genentech, Inc. System for antibody expression and assembly
US20040235068A1 (en) * 2001-09-05 2004-11-25 Levinson Arthur D. Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
EP2143437B1 (en) 2001-09-18 2013-08-21 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
EP2990394A1 (en) 2001-11-30 2016-03-02 Biogen MA Inc. Antibodies against monocyte chemotactic proteins
US7572763B2 (en) * 2002-02-21 2009-08-11 Wyeth Follistatin domain containing proteins
US20040009169A1 (en) 2002-02-25 2004-01-15 Julie Taylor Administration of agents for the treatment of inflammation
US20060235208A1 (en) * 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
US8093357B2 (en) * 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
US20070275460A1 (en) * 2003-03-03 2007-11-29 Xencor.Inc. Fc Variants With Optimized Fc Receptor Binding Properties
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US20100311954A1 (en) * 2002-03-01 2010-12-09 Xencor, Inc. Optimized Proteins that Target Ep-CAM
US20080254027A1 (en) * 2002-03-01 2008-10-16 Bernett Matthew J Optimized CD5 antibodies and methods of using the same
US8388955B2 (en) * 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
US20080260731A1 (en) * 2002-03-01 2008-10-23 Bernett Matthew J Optimized antibodies that target cd19
US20090042291A1 (en) * 2002-03-01 2009-02-12 Xencor, Inc. Optimized Fc variants
US20070148171A1 (en) * 2002-09-27 2007-06-28 Xencor, Inc. Optimized anti-CD30 antibodies
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US20030180292A1 (en) * 2002-03-14 2003-09-25 Idec Pharmaceuticals Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
EP1494711A4 (en) * 2002-03-19 2008-05-28 Abgenix Inc Methods for treating chronic obstructive pulmonary disease (copd)
EP2289942B1 (en) 2002-04-10 2013-07-31 Genentech, Inc. Anti-HER2 antibody variants
JP2005536190A (en) 2002-04-16 2005-12-02 ジェネンテック・インコーポレーテッドGenentech,Inc. Compositions and methods for the diagnosis and treatment of tumors
US6916904B2 (en) * 2002-04-24 2005-07-12 Zolaris Biosciences, Llc Inhibition of immune complex formation
JP3885658B2 (en) * 2002-05-13 2007-02-21 住友電気工業株式会社 Heterojunction bipolar transistor
EP2305710A3 (en) 2002-06-03 2013-05-29 Genentech, Inc. Synthetic antibody phage libraries
JP4753578B2 (en) * 2002-06-03 2011-08-24 ジェネンテック, インコーポレイテッド Synthetic antibody phage libraries
DK2311432T3 (en) 2002-06-07 2015-02-02 Dyax Corp Modified Kunitz domain polypeptides and their use in reducing ischemia or the onset of a systemic inflammatory response associated with a surgical procedure
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
EP1551453A4 (en) * 2002-06-17 2007-04-25 Us Gov Health & Human Serv Specificity grafting of a murine antibody onto a human framework
US7628988B2 (en) 2002-06-27 2009-12-08 The General Hospital Corporation Methods and compositions for treating type 1 diabetes
US7582313B2 (en) 2002-06-27 2009-09-01 The General Hospital Corporation Methods of organ regeneration using Hox 11-expressing pluripotent cells
US20040001827A1 (en) * 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
US20050287153A1 (en) * 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US20040208877A1 (en) * 2002-07-01 2004-10-21 Avigdor Levanon Antibodies and uses thereof
US20040202665A1 (en) * 2002-07-01 2004-10-14 Janette Lazarovits Compositions and methods for therapeutic treatment
US7435419B2 (en) 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
US7794716B2 (en) 2002-07-25 2010-09-14 Glenveigh Pharmaceuticals, Llc Antibody composition and passive immunization against pregnancy-induced hypertension
DK1534335T4 (en) 2002-08-14 2015-10-05 Macrogenics Inc Fcgammariib-specific antibodies, and methods of use thereof
US7166576B2 (en) * 2002-08-28 2007-01-23 Dyax Corp. Methods for preserving organs and tissues
EP1539234A4 (en) * 2002-09-05 2006-02-15 Medimmune Inc Methods of preventing or treating cell malignancies by administering cd2 antagonists
DK1931709T3 (en) 2005-10-03 2017-03-13 Xencor Inc Fc variants with optimized Fc receptor binding properties
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US8399618B2 (en) 2004-10-21 2013-03-19 Xencor, Inc. Immunoglobulin insertions, deletions, and substitutions
US8883147B2 (en) 2004-10-21 2014-11-11 Xencor, Inc. Immunoglobulins insertions, deletions, and substitutions
US8101720B2 (en) * 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
KR20050057631A (en) 2002-10-10 2005-06-16 메르크 파텐트 게엠베하 Bispecific anti-erb-b antibodies and their use in tumor therapy
DK2891666T3 (en) 2002-10-16 2017-10-02 Purdue Pharma Lp Antibodies that bind cell-associated CA 125 / O722P, and methods of use thereof
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
WO2004042017A3 (en) * 2002-10-31 2004-07-15 Genentech Inc Methods and compositions for increasing antibody production
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US8505468B2 (en) * 2002-11-19 2013-08-13 Sharp Kabushiki Kaisha Substrate accommodating tray
EP1572972A4 (en) * 2002-11-21 2007-11-21 Genentech Inc Therapy of non-malignant diseases or disorders with anti-erbb2 antibodies
EP2308968A1 (en) * 2002-11-26 2011-04-13 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US7888479B2 (en) * 2002-11-27 2011-02-15 Biogen Idec Ma Inc. Humanized antibodies against monocyte chemotactric proteins
JP4351674B2 (en) * 2002-12-16 2009-10-28 ジェネンテック・インコーポレーテッドGenentech,Inc. Immunoglobulin variants and their use and their use
JP4494977B2 (en) * 2002-12-17 2010-06-30 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung Mice that bind to gd2 14.18 antibody in the humanized antibody (h14.18) and il-2 fusion protein
JP2006513187A (en) * 2002-12-23 2006-04-20 ライナット ニューロサイエンス コーポレイション A method for treating a taxol-induced sensory neuropathy
CA2936742A1 (en) 2002-12-24 2004-07-15 Rinat Neuroscience Corp. Anti-ngf antibodies and methods using same
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
US7488475B2 (en) 2003-01-21 2009-02-10 Arius Research, Inc. Antibody therapy of tumors
EP1585768A2 (en) * 2003-01-23 2005-10-19 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
KR20050114212A (en) 2003-01-24 2005-12-05 엘란 파마슈티칼스, 인크. Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
JP3803790B2 (en) * 2003-02-17 2006-08-02 株式会社東北テクノアーチ The novel diabody-type bispecific antibody
JP2006525960A (en) 2003-02-19 2006-11-16 ライナット ニューロサイエンス コーポレイション Methods for treating pain by administration of nerve growth factor agonists and NSAID, and compositions containing them
CN102225194B (en) 2003-03-12 2014-07-16 健泰科生物技术公司 Use of Bv8 and/or EG-VEGF to promote hematopoiesis
US20070014786A1 (en) * 2003-03-20 2007-01-18 Rinat Neuroscience Corp. Methods for treating taxol-induced gut disorder
EP1622941A2 (en) * 2003-03-20 2006-02-08 ImClone Systems Incorporated Method of producing an antibody to epidermal growth factor receptor
JP5503837B2 (en) 2003-03-26 2014-05-28 ポール,サッドヒル Covalent binding of a ligand to nucleophilic proteins induced by non-covalent bonds
EP1615946A4 (en) * 2003-03-26 2009-05-27 Sudhir Paul Proteolytic and covalent antibodies
US8246957B2 (en) * 2003-03-27 2012-08-21 Sudhir Paul Lupus antibodies for passive immunotherapy of HIV/AIDS
US7235376B2 (en) * 2003-03-28 2007-06-26 Receptor Biologix, Inc. Gastrin hormone immunoassays
DK1613350T3 (en) 2003-04-09 2009-06-22 Genentech Inc Treatment of autoimmune disease in a patient with an inadequate response to a TNF-alpha inhibitor
EP2316487B1 (en) 2003-04-11 2014-06-11 MedImmune, LLC Recombinant IL-9 antibodies & uses thereof
US20080213169A1 (en) * 2003-04-14 2008-09-04 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD59
US20060140963A1 (en) * 2003-04-14 2006-06-29 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD59
US20080025977A1 (en) * 2003-04-14 2008-01-31 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD59
US7189694B2 (en) * 2003-04-18 2007-03-13 University Of Florida Research Foundation, Inc. Inhibitors of autophosphorylation protein kinases
US7321065B2 (en) 2003-04-18 2008-01-22 The Regents Of The University Of California Thyronamine derivatives and analogs and methods of use thereof
US20040208876A1 (en) 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
US8613922B2 (en) 2003-04-24 2013-12-24 The University Of North Carolina At Chapel Hill Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP)
EP1622644A2 (en) * 2003-05-12 2006-02-08 University Of Florida Research Foundation, Inc. Materials and methods for immunizing against fiv infection
US7658927B2 (en) * 2003-05-12 2010-02-09 University Of Florida Research Foundation, Inc. Materials and methods for immunizing against FIV infection
ES2640669T3 (en) 2003-05-19 2017-11-03 Prothena Biosciences Limited Truncated fragments of alpha-synuclein in Lewy body disease
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
WO2005000896A3 (en) * 2003-05-30 2005-02-10 Charles Eigenbrot Polypeptides that bind an anti-tissue factor antibody and uses thereof
US7405274B2 (en) 2003-06-04 2008-07-29 Fibrogen, Inc. Connective tissue growth factor antibodies
US20050163775A1 (en) * 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
ES2538469T3 (en) 2003-06-05 2015-06-22 Genentech, Inc. Combination therapy for B cell disorders
CN1279056C (en) * 2003-06-06 2006-10-11 马菁 Specific antibody of tumor-associated antigen SM5-1 and use thereof
DE602004029252D1 (en) 2003-06-13 2010-11-04 Biogen Idec Inc Aglycosyl anti-CD154 (CD40 ligand) antibodies and their uses
US20050152906A1 (en) * 2003-06-30 2005-07-14 Avigdor Levanon Specific human antibodies
WO2005000086A3 (en) * 2003-06-30 2007-03-08 Ofer Mandelboim FRAGMENTS OF NKp44 AND NKp46 FOR TARGETING VIRAL-INFECTED AND TUMOR CELLS
US20050266009A1 (en) * 2003-06-30 2005-12-01 Savient Pharmaceuticals, Inc. Antibodies and uses thereof
US20050069955A1 (en) * 2003-06-30 2005-03-31 Daniel Plaksin Antibodies and uses thereof
JP2008500005A (en) * 2003-07-15 2008-01-10 バロス リサーチ インスティテュート Compositions and methods for immunotherapy of cancer and infectious diseases
WO2005010163A3 (en) * 2003-07-15 2006-08-31 Barros Res Inst Compositions and methods for immunotherapy of human immunotherapy of human immunodeficiency virus (hiv)
CA2531595C (en) 2003-07-28 2015-12-08 Genentech, Inc. Reducing protein a leaching during protein a affinity chromatography
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US7758859B2 (en) * 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
JP2007511738A (en) 2003-08-08 2007-05-10 ジーンニュース インコーポレーテッド Biomarkers and uses thereof osteoarthritis
US20060228350A1 (en) * 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
WO2005042743A8 (en) * 2003-08-18 2013-11-21 Medimmune, Inc. Humanization of antibodies
CA2537055A1 (en) * 2003-08-22 2005-04-21 Medimmune, Inc. Humanization of antibodies
WO2005027966A3 (en) * 2003-09-05 2005-09-15 Genentech Inc Antibodies with altered effector functions
GB2406094B (en) * 2003-09-17 2007-06-06 Antisoma Plc Modified antibody comprising an amino acid substitution mutation which confers increased stability
US20050176028A1 (en) * 2003-10-16 2005-08-11 Robert Hofmeister Deimmunized binding molecules to CD3
EP2118300B1 (en) 2007-02-23 2015-05-27 Prothena Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
EP2478912B1 (en) * 2003-11-06 2016-08-31 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
WO2005047324A2 (en) * 2003-11-10 2005-05-26 Schering Corp Interleukin-10 antibodies
US7572443B2 (en) * 2003-11-13 2009-08-11 California Pacific Medical Center Anti-PECAM therapy for metastasis suppression
EP2412725A3 (en) 2003-11-17 2012-04-25 Genentech, Inc. Antibodies against CD79b for the treatment of tumor of hematopoeitic origin
DE602004027291D1 (en) 2003-11-25 2010-07-01 Us Gov Health & Human Serv Mutated anti-CD22 antibodies and immunoconjugates
US20060003412A1 (en) * 2003-12-08 2006-01-05 Xencor, Inc. Protein engineering with analogous contact environments
US20070249809A1 (en) * 2003-12-08 2007-10-25 Xencor, Inc. Protein engineering with analogous contact environments
WO2005077981A3 (en) * 2003-12-22 2006-02-16 Xencor Inc Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
WO2005062955A3 (en) * 2003-12-23 2006-06-22 Rinat Neuroscience Corp Agonist anti-trkc antibodies and methods using same
CA2554729A1 (en) * 2004-01-27 2005-08-11 University Of Southern California Polymer-bound antibody cancer therapeutic agent
DK1718338T3 (en) 2004-02-02 2015-08-10 Engeneic Molecular Delivery Pty Ltd Compositions and methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells
US20070281323A1 (en) 2004-02-03 2007-12-06 Wolfert Robert L Methods Of Detecting Lp-PLA2 Activity
CN1965082A (en) * 2004-02-06 2007-05-16 尼莫克斯股份有限公司 Humanized antibody
US7973134B2 (en) * 2004-07-07 2011-07-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways
US7935790B2 (en) * 2004-10-04 2011-05-03 Cell Singaling Technology, Inc. Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways
WO2005079479A3 (en) * 2004-02-17 2006-01-12 Absalus Inc Super-humanized antibodies against respiratory syncytial virus
ES2337473T3 (en) 2004-02-19 2010-04-26 Genentech, Inc. repairers antibodies with CDRs.
US7875598B2 (en) 2004-03-04 2011-01-25 The Regents Of The University Of California Compositions useful for the treatment of microbial infections
EP1730170A4 (en) * 2004-03-10 2008-09-03 Trinity Therapeutics Inc Method for inhibiting immune complex formation in a subjetc
US7273608B2 (en) * 2004-03-11 2007-09-25 City Of Hope Humanized anti-CEA T84.66 antibody and uses thereof
WO2005092925A3 (en) * 2004-03-24 2006-05-11 Xencor Inc Immunoglobulin variants outside the fc region
RU2386638C2 (en) 2004-03-31 2010-04-20 Дженентек, Инк. Humanised anti-tgf-beta-antibody
CA2562024C (en) * 2004-04-07 2014-05-27 Rinat Neuroscience Corp. Methods for treating bone cancer pain by administering a nerve growth factor antagonist
WO2005099756A3 (en) * 2004-04-08 2006-06-15 David B Agus ErbB ANTAGONISTS FOR PAIN THERAPY
US7785903B2 (en) * 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
US20150017671A1 (en) 2004-04-16 2015-01-15 Yaping Shou Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
EP1735000A2 (en) * 2004-04-16 2006-12-27 Genentech, Inc. Method for augmenting b cell depletion
US20060002930A1 (en) * 2004-04-16 2006-01-05 Genentech, Inc. Treatment of disorders
CN1993143A (en) 2004-06-04 2007-07-04 健泰科生物技术公司 Method for treating multiple sclerosis
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
US20090098142A1 (en) * 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
JP2008504289A (en) * 2004-06-25 2008-02-14 メディミューン,インコーポレーテッド Increased production of recombinant antibodies in mammalian cells by site-directed mutagenesis
US6986264B1 (en) * 2004-07-15 2006-01-17 Carrier Corporation Economized dehumidification system
EP1791563A4 (en) 2004-07-26 2009-07-08 Biogen Idec Inc Anti-cd154 antibodies
KR101068289B1 (en) 2004-07-30 2011-09-28 리나트 뉴로사이언스 코퍼레이션 Antibodies directed against amyloid-beta peptide and methods using same
WO2006017531A3 (en) 2004-08-06 2006-04-27 Genentech Inc Assays and methods using biomarkers
KR101235479B1 (en) 2004-08-06 2013-02-20 제넨테크, 인크. Assays and methods using biomarkers
CA2577133A1 (en) * 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
CA2478458A1 (en) * 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
EP1791959A4 (en) 2004-08-26 2009-03-18 Enegenic Gene Therapy Pty Ltd Delivering functional nucleic acids to mammalian cells via bacterially derived, intact minicells
RU2404991C2 (en) * 2004-09-02 2010-11-27 Дженентек, Инк. FcγRIIB RECEPTOR ANTIBODIES AND APPLICATION THEREOF
US7662926B2 (en) * 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
US7655229B2 (en) * 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
EP1789446A2 (en) * 2004-09-02 2007-05-30 Genentech, Inc. Heteromultimeric molecules
DK1784426T3 (en) 2004-09-03 2012-03-12 Genentech Inc Humanized anti-beta7 antagonists, and uses thereof
US20060074225A1 (en) * 2004-09-14 2006-04-06 Xencor, Inc. Monomeric immunoglobulin Fc domains
KR101333168B1 (en) 2004-09-22 2013-11-28 리셉터 바이오로직스 인크 Monoclonal antibodies to progastrin
KR101270829B1 (en) 2004-09-23 2013-06-07 제넨테크, 인크. Cystein engineered antibodies and conjugates
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
CA2581336A1 (en) 2004-09-24 2006-03-30 S. Ananth Karumanchi Methods of diagnosing and treating complications of pregnancy
ES2398528T3 (en) * 2004-10-04 2013-03-19 Genentech, Inc. Modulators activator hepatocyte growth factor
RU2007116973A (en) * 2004-10-05 2008-11-20 Дженентек, Инк. (Us) Therapeutic agents with reduced toxicity
US20060134105A1 (en) * 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
EP2319492A3 (en) 2004-10-21 2011-08-10 Genentech, Inc. Method for treating intraocular neovascular diseases
WO2006047639A3 (en) 2004-10-27 2007-04-19 Kelly Carles-Knich Modulation of antibody specificity by tailoring the affinity to cognate antigens
CA2585849A1 (en) * 2004-10-29 2006-05-11 Elusys Therapeutics, Inc. Use of cr1-binding molecules in clearance and induction of immune responses
US20060222653A1 (en) * 2004-11-12 2006-10-05 Xencor, Inc. Antibodies operably linked to selected chemoattractants
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
WO2006053301A3 (en) 2004-11-12 2007-04-05 Xencor Inc Fc variants with altered binding to fcrn
US20070135620A1 (en) * 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
CA2586909A1 (en) * 2004-11-12 2006-12-14 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the n terminus
US8367805B2 (en) * 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
CA2587903A1 (en) 2004-11-17 2006-05-26 Amgen Fremont Inc. Fully human monoclonal antibodies to il-13
WO2006055871A3 (en) 2004-11-19 2006-08-03 Biogen Idec Inc Treatment for multiple sclerosis
GB0425713D0 (en) * 2004-11-23 2004-12-22 Baker Matthew Immunogencity testing and antibody selection methods
EP1817059A2 (en) 2004-12-01 2007-08-15 Genentech, Inc. Conjugates of 1,8-bis-naphthalimides with an antibody
US20070134243A1 (en) * 2004-12-01 2007-06-14 Gazzard Lewis J Antibody drug conjugates and methods
CN101111263A (en) * 2004-12-03 2008-01-23 比奥根艾迪克Ma公司 Delaying or preventing onset of multiple sclerosis
JP2008523073A (en) * 2004-12-07 2008-07-03 ジェネンテック・インコーポレーテッドGenentech,Inc. Selection of patients for treatment with Her inhibitors
CA2589017A1 (en) * 2004-12-15 2006-06-22 Neuralab Limited Amyloid beta antibodies for use in improving cognition
US8916165B2 (en) 2004-12-15 2014-12-23 Janssen Alzheimer Immunotherapy Humanized Aβ antibodies for use in improving cognition
US7807789B2 (en) * 2004-12-21 2010-10-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
EP2290086A3 (en) 2004-12-22 2011-10-19 Genentech, Inc. Methods for producing soluble multi-membrane-spanning proteins
KR20070100299A (en) * 2004-12-22 2007-10-10 암브룩스, 인코포레이티드 Methods for expression and purification of recombinant human growth hormone
EP1841793B1 (en) 2005-01-07 2010-03-31 Diadexus, Inc. Ovr110 antibody compositions and methods of use
JP2008526998A (en) * 2005-01-13 2008-07-24 ジェネンテック・インコーポレーテッドGenentech,Inc. Method of treatment
US20080102054A1 (en) * 2005-01-18 2008-05-01 Faustman Denise L Compositions Containing Agm Cells And Methods Of Use Thereof
US20080161251A1 (en) 2005-01-21 2008-07-03 Astex Therapeutics Limited Pharmaceutical Compounds
KR20150083139A (en) 2005-01-21 2015-07-16 제넨테크, 인크. Fixed dosing of her antibodies
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
JP2008528668A (en) 2005-02-03 2008-07-31 アンチトープ リミテッド Human Antibodies and proteins
EP2404937A1 (en) 2005-02-07 2012-01-11 GlycArt Biotechnology AG Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
EP1846577B1 (en) 2005-02-07 2012-07-04 GeneNews Inc. Method of diagnosing osteoarthritis employing the biomarkers IL13RA1 and CPT1A
CA2595395A1 (en) * 2005-02-09 2006-08-17 Genentech, Inc. Inhibiting her2 shedding with matrix metalloprotease antagonists
KR20070112801A (en) 2005-02-14 2007-11-27 유니버시티 오브 아이오와 리써치 파운데이션 Methods and reagents for treatment and diagnosis of age-related macular degeneration
CA2597945C (en) 2005-02-17 2016-07-12 Biogen Idec Ma Inc. Treating neurological disorders
EP1850874B1 (en) 2005-02-23 2013-10-16 Genentech, Inc. Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
US20060193849A1 (en) * 2005-02-25 2006-08-31 Antisoma Plc Biological materials and uses thereof
JP2008531719A (en) 2005-03-02 2008-08-14 バイオジェン・アイデック・エムエイ・インコーポレイテッド KIM-1 antibody for the treatment of Th2-mediated condition
EP1858545A2 (en) * 2005-03-04 2007-11-28 Curedm Inc. Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions
US20090142338A1 (en) * 2005-03-04 2009-06-04 Curedm, Inc. Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
CA2600929A1 (en) * 2005-03-04 2006-09-14 Biogen Idec Ma Inc. Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues
EP1863531A1 (en) 2005-03-19 2007-12-12 Medical Research Council Improvements in or relating to treatment and prevention of viral infections
US20060240487A1 (en) * 2005-03-23 2006-10-26 Nowak John A Detection of GDF-8 modulating agents
WO2006105021A3 (en) 2005-03-25 2007-03-08 Tolerrx Inc Gitr binding molecules and uses therefor
EP1863519B1 (en) 2005-03-31 2013-09-25 The General Hospital Corporation Modulating hgf/hgfr activity for treating lymphodema
ES2536915T3 (en) 2005-04-04 2015-05-29 Biogen Idec Ma Inc. Methods and products for assessing an immune response to a therapeutic protein
EP1885396A2 (en) 2005-05-04 2008-02-13 Quark Pharmaceuticals, Inc. Recombinant antibodies against cd55 and cd59 and uses thereof
JP5047947B2 (en) 2005-05-05 2012-10-10 デューク ユニバーシティ Anti-cd19 antibody treatment for autoimmune disease
JP5065253B2 (en) 2005-05-06 2012-10-31 ザイモジェネティクス, インコーポレイテッド Il-31 monoclonal antibodies and their use
EP1885388B1 (en) 2005-05-10 2013-09-11 Biogen Idec MA Inc. Treating and evaluating inflammatory disorders
US8088908B2 (en) 2005-05-10 2012-01-03 City Of Hope Humanized anti-prostate stem cell antigen monoclonal antibody
CA2540547C (en) 2005-05-13 2016-08-16 Genentech, Inc. Herceptin adjuvant therapy
CA2609667C (en) 2005-05-25 2011-02-22 Curedm, Inc. Human proislet peptide, derivatives and analogs thereof, and methods of using same
JP2008541781A (en) 2005-06-06 2008-11-27 ジェネンテック・インコーポレーテッドGenentech,Inc. Their use for the characterization of transgenic animals, and genes for different genes
RU2415151C2 (en) 2005-06-07 2011-03-27 Эсбатек Аг STABLE AND SOLUBLE ANTIBODIES, INHIBITING TNFα
WO2006138219A3 (en) 2005-06-13 2007-04-12 Biogen Idec Inc Methods of diagnosis / prognosis of inflammatory conditions
WO2006138739A3 (en) 2005-06-17 2007-12-21 Tolerx Inc Ilt3 binding molecules and uses therefor
US7777008B2 (en) 2006-06-19 2010-08-17 Tolerx, Inc. ILT3 binding molecules and uses therefor
JP2008546805A (en) 2005-06-23 2008-12-25 メディミューン,エルエルシー Antibody preparation with optimal aggregation and fragmentation profile
US8343928B2 (en) 2005-07-07 2013-01-01 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine side-chain replacements at the C-terminus
US8871720B2 (en) * 2005-07-07 2014-10-28 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
CN102875681A (en) 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 Anti-alpha v beta 6 antibodies and uses thereof
US7494648B2 (en) * 2005-08-02 2009-02-24 Hoffmann-La Roche Inc. Cancerous disease modifying antibodies
US7452979B2 (en) 2005-08-02 2008-11-18 Arius Research, Inc. Cancerous disease modifying antibodies
US7456259B2 (en) 2005-08-02 2008-11-25 Arius Research, Inc. Cancerous disease modifying antibodies
US7411046B2 (en) 2005-08-02 2008-08-12 Arius Research Inc Cancerous disease modifying antibodies
US7452978B2 (en) * 2005-08-02 2008-11-18 Arius Research, Inc. Cancerous disease modifying antibodies
US7456258B2 (en) 2005-08-02 2008-11-25 Arius Research, Inc. Cancerous disease modifying antibodies
US7700299B2 (en) 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
US20090258442A1 (en) * 2006-08-31 2009-10-15 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
WO2007027906A3 (en) * 2005-08-31 2010-11-18 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
US20100151495A9 (en) * 2005-08-31 2010-06-17 Cell Signaling Technolgy, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
CA2621539A1 (en) * 2005-09-06 2007-03-15 Trinity Therapeutics, Inc. Methods for treating immune mediated neurological diseases
US8945573B2 (en) 2005-09-08 2015-02-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Targeted identification of immunogenic peptides
JP4860703B2 (en) * 2005-10-06 2012-01-25 ゼンコー・インコーポレイテッドXencor、 Inc. Optimized anti-cd30 antibody
EP1940881B1 (en) 2005-10-11 2016-11-30 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
US7862812B2 (en) 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
EP2465870A1 (en) 2005-11-07 2012-06-20 Genentech, Inc. Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
WO2007056411A3 (en) * 2005-11-08 2007-08-30 Genentech Inc Method of producing pan-specific antibodies
WO2007061679A1 (en) * 2005-11-17 2007-05-31 Millennium Pharmaceuticals, Inc. HUMANIZED IMMUNOGLOBULIN REACTIVE WITH α4β7 INTEGRIN
EP1951892A4 (en) 2005-11-22 2009-01-14 Univ Pennsylvania Antibody treatment of alzheimer's and related diseases
ES2618543T3 (en) * 2005-11-23 2017-06-21 Genentech, Inc. Methods and compositions related to B cell assays
KR101434682B1 (en) * 2005-12-02 2014-08-27 제넨테크, 인크. Binding polypeptides and uses thereof
US20070237764A1 (en) * 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
WO2007120334A3 (en) 2005-12-15 2008-05-29 Genentech Inc Methods and compositions for targeting polyubiquitin
EP1968633B2 (en) 2006-01-04 2017-11-01 Institut National de la Santé et de la Recherche Medicale Combination therapy using anti-egfr and anti-her2 antibodies
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
US20070175313A1 (en) * 2006-01-31 2007-08-02 Kevin Vandervliet MP3 player holder assembly
JP2009527227A (en) 2006-02-17 2009-07-30 ジェネンテック・インコーポレーテッドGenentech,Inc. Gene disruption, compositions and methods related thereto
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
US8021839B2 (en) * 2006-02-24 2011-09-20 Investigen, Inc. Methods and compositions for detecting polynucleotides
EP1999148B8 (en) 2006-03-06 2014-03-05 Medlmmune, LLC Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
EP2359834B1 (en) 2006-03-15 2016-11-09 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
US20090220504A1 (en) 2006-03-21 2009-09-03 Anan Chuntharapai Combinatorial therapy
EP2389947A1 (en) 2006-03-23 2011-11-30 Novartis AG Anti-tumor cell antigen antibody therapeutics
JP5082104B2 (en) 2006-03-23 2012-11-28 国立大学法人東北大学 Highly functional bispecific antibody
JP4419976B2 (en) 2006-03-24 2010-02-24 オンキヨー株式会社 Speaker diaphragm and speaker
WO2007126455A3 (en) 2006-04-05 2008-01-03 Genentech Inc Method for using boc/cdo to modulate hedgehog signaling
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
WO2008036437A3 (en) 2006-04-19 2008-10-02 Genentech Inc Novel gene disruptions, compositions and methods relating thereto
US20090298093A1 (en) * 2006-04-27 2009-12-03 Roberto Polakiewicz Reagents for the Detection of Protein Phosphorylation in ATM & ATR Kinase Signaling Pathways
US7745584B2 (en) 2006-05-22 2010-06-29 California Institute Of Technology Antibodies to sulfated carbohydrates
CA2654000A1 (en) * 2006-06-06 2008-05-22 Genentech, Inc. Anti-dll4 antibodies and methods using same
KR101510753B1 (en) * 2006-06-07 2015-04-10 바이오얼라이언스 씨.브이. Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
EP2037961B1 (en) 2006-06-14 2015-11-11 MacroGenics, Inc. Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity
EP2046384A4 (en) 2006-06-15 2009-12-02 Fibron Ltd Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
ES2599319T3 (en) 2006-06-26 2017-02-01 Macrogenics, Inc. Fc RIIB-specific antibodies and methods of use thereof
CA2656224C (en) 2006-06-26 2018-01-09 Macrogenics, Inc. Combination of fc.gamma.riib antibodies and cd20-specific antibodies and methods of use thereof
US7749772B1 (en) 2006-06-29 2010-07-06 Varian, Inc. Antibody and immunoassays for determining the presence of Δ9-Tetrahydrocannabinol
JP5829004B2 (en) 2006-06-30 2015-12-09 ノボ・ノルデイスク・エー/エス Anti-nkg2a antibody and its use
US20080003230A1 (en) 2006-07-03 2008-01-03 Adair Charles D Composition for modulating the expression of cell adhesion molecules
EP1983002A3 (en) 2007-04-19 2009-03-11 Peter Hornbeck Tyrosine phosphorylation sites and antibodies specific for them
KR101528939B1 (en) 2006-07-18 2015-06-15 사노피 Antagonist antibody against epha2 for the treatment of cancer
ES2661952T3 (en) 2006-08-04 2018-04-04 Medimmune Limited human antibodies against ERBB2
EP2057465A4 (en) 2006-08-09 2010-04-21 Homestead Clinical Corp Organ-specific proteins and methods of their use
US7939636B2 (en) * 2006-08-11 2011-05-10 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in c-Src signaling pathways
JP2010502573A (en) 2006-08-11 2010-01-28 ユニヴァーシティ オブ メディスン アンド デンティストリー オブ ニュー ジャージー Dual sensitizer containing luminescent compound and conjugates and the use thereof
EP2383297B1 (en) 2006-08-14 2013-01-16 Xencor Inc. Optimized antibodies that target CD19
KR101136763B1 (en) 2006-08-21 2012-04-24 에프. 호프만-라 로슈 아게 Tumor therapy with an anti-vegf antibody
EP2471816A1 (en) 2006-08-30 2012-07-04 Genentech, Inc. Multispecific antibodies
CA2660175C (en) 2006-09-01 2015-05-12 Zymogenetics, Inc. Variable region sequences of il-31 monoclonal antibodies and methods of use
JP5695317B2 (en) 2006-09-05 2015-04-01 アレクシオン ファーマシューティカルズ, インコーポレイテッド Methods and compositions for the treatment of antibody mediated neuropathies
US7846895B2 (en) 2006-09-06 2010-12-07 The Regents Of The University Of California Selectively targeted antimicrobial peptides and the use thereof
US20150359850A1 (en) 2009-11-25 2015-12-17 Santa Maria Biotherapeutics, Inc. Administration of an anti-activin-a compound to a subject
ES2383710T3 (en) 2006-09-08 2012-06-25 Medimmune, Llc Humanized anti-CD19 antibodies and their use in the treatment of tumors, autoimmune diseases and transplantation
WO2008033782A8 (en) 2006-09-12 2008-10-02 John Chant Methods and compositions for the diagnosis and treatment of lung cancer using pdgfra, kit or kdr gene as genetic marker
WO2008036688A3 (en) 2006-09-18 2009-09-24 Xencor, Inc. Optimized antibodies that target hm1.24
WO2008042941A3 (en) * 2006-10-04 2008-12-11 Medimmune Llc Humanized anti-ephb4 antibodies and their use in treatment of oncology and vasculogenesis-related disease
US9382327B2 (en) 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
KR101485202B1 (en) * 2006-10-11 2015-01-22 안티토페 리미티드 T cell epitope databases
EP2073807A1 (en) 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmaceutical combinations
EP2076287A2 (en) * 2006-10-12 2009-07-08 Wyeth Methods and compositions with reduced opalescence
JP5528806B2 (en) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッドAstex Therapeutics Limited Complex drug
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
WO2008070344A3 (en) * 2006-10-27 2008-11-20 Lpath Therapeutics Inc Compositions and methods for binding sphingosine-1-phosphate
KR20140116546A (en) 2006-10-27 2014-10-02 제넨테크, 인크. Antibodies and immunoconjugates and uses therefor
US8361465B2 (en) * 2007-10-26 2013-01-29 Lpath, Inc. Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
EP2471818A1 (en) 2006-11-02 2012-07-04 Genentech, Inc. Humanized anti-factor D antibodies and uses thereof
WO2008055260A3 (en) 2006-11-03 2009-01-08 Wyeth Corp Glycolysis-inhibiting substances in cell culture
EP2092058A1 (en) * 2006-11-13 2009-08-26 Arius Research Inc. Cancerous disease modifying antibodies
CA2668484A1 (en) * 2006-11-13 2008-05-22 F. Hoffmann-La Roche Ag Cancerous disease modifying antibodies 180706-02
US8785400B2 (en) * 2006-11-22 2014-07-22 Curedm Group Holdings, Llc Methods and compositions relating to islet cell neogenesis
WO2008066752A8 (en) 2006-11-22 2009-07-09 Adnexus A Bristol Myers Squibb Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
US8945565B2 (en) 2006-12-01 2015-02-03 Selexys Pharmaceuticals Corporation Methods of treating inflammatory or thrombotic conditions with anti-P-selectin antibodies
EP2662091B1 (en) 2006-12-01 2018-08-22 Selexys Pharmaceuticals Corporation Anti-P-selectin antibodies and methods of using the same to treat inflammatory diseases
US20110212096A1 (en) 2006-12-01 2011-09-01 Scott Rollins Anti-p-selectin antibodies and methods of their use and identification
US8288110B2 (en) * 2006-12-04 2012-10-16 Perkinelmer Health Sciences, Inc. Biomarkers for detecting cancer
CN101678100A (en) 2006-12-06 2010-03-24 米迪缪尼有限公司 methods of treating systemic lupus erythematosus
EP2716658A3 (en) * 2006-12-20 2014-10-08 Mmrglobal, Inc. Antibodies and methods for making and using them
DE102007001370A1 (en) * 2007-01-09 2008-07-10 Curevac Gmbh RNA encoded antibody
EP2629094A1 (en) 2007-01-24 2013-08-21 Carnegie Mellon University Optical biosensors
US20100119526A1 (en) * 2007-01-26 2010-05-13 Bioinvent International Ab DLL4 Signaling Inhibitors and Uses Thereof
US20100144599A1 (en) 2007-02-02 2010-06-10 Bristol-Myers Squibb Company Vegf pathway blockade
WO2008100805A3 (en) 2007-02-09 2008-10-09 Richard Carano Anti-robo4 antibodies and uses therefor
JP5642972B2 (en) 2007-02-21 2014-12-17 ユニバーシティー オブ マサチューセッツUniversity of Massachusetts Human antibodies and uses thereof against hepatitis C virus (HCV)
US7771947B2 (en) * 2007-02-23 2010-08-10 Investigen, Inc. Methods and compositions for rapid light-activated isolation and detection of analytes
US20090081659A1 (en) 2007-03-07 2009-03-26 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
JP2010521180A (en) 2007-03-14 2010-06-24 ノバルティス アーゲー Treating cancer, APCDD1 inhibitor for the diagnosis or detection
WO2008116103A3 (en) * 2007-03-22 2009-01-08 Imclone Systems Inc Stable antibody formulations
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
WO2008118324A3 (en) 2007-03-26 2008-12-18 Stacy Ferguson Composition and method of treating cancer with an anti-uroplakin ib antibody
EP1975184A3 (en) 2007-03-26 2008-11-26 Cell Signaling Technology, Inc. Serine or threonine phosphorylation sites
US20080238709A1 (en) * 2007-03-28 2008-10-02 Faramarz Vaziri One-way communication apparatus with dynamic key generation
WO2008121616A3 (en) 2007-03-30 2009-01-08 Medimmune Inc Antibodies with decreased deamidation profiles
US20100291024A1 (en) * 2007-03-30 2010-11-18 Xuebin Qin Methods and compositions for the treatment of proliferative and pathogenic diseases
CN101715489B (en) 2007-03-30 2016-05-25 因詹尼克分子递送控股有限公司 For in vivo delivery to a mammalian cell, comprising the plasmid-free functional nucleic acid, the bacterially derived intact minicell
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US7977462B2 (en) 2007-04-19 2011-07-12 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
EP1983003A3 (en) 2007-04-19 2009-03-11 Peter Hornbeck Tyrosine phosphorylation sites and antibodies specific for them
JP2010527916A (en) * 2007-04-23 2010-08-19 ワイス・エルエルシー Il-13 method of treating related disorders and compositions and methods of monitoring the therapeutic
US20090053831A1 (en) 2007-05-01 2009-02-26 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
US20100136627A1 (en) 2007-05-04 2010-06-03 Technophage,Investigacao E Desenvolvimento Em Biotechnologia, Sa Engineered Rabbit Antibody Variable Domains and Uses Thereof
CN101861168B (en) 2007-05-07 2014-07-02 米迪缪尼有限公司 Anti-ICOS antibodies and their use in treatment of oncology, transplantation and autoimmune disease
EP2376126B1 (en) 2008-11-25 2017-12-20 AlderBio Holdings LLC Antagonists of il-6 to prevent or treat thrombosis
WO2009055074A3 (en) * 2007-10-25 2009-09-11 Wyeth Erbb2 binding proteins and use thereof
US20090304590A1 (en) * 2007-05-29 2009-12-10 Wyeth Therapeutic compositions and methods
US20090258005A1 (en) * 2007-05-29 2009-10-15 Trubion Pharmaceuticals Inc. Therapeutic compositions and methods
WO2008150841A1 (en) * 2007-05-30 2008-12-11 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
US9163091B2 (en) * 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
US20110064744A1 (en) * 2007-05-30 2011-03-17 Sabbadini Roger A Prevention and treatment of pain using antibodies to lysophosphatidic acid
WO2008154249A3 (en) * 2007-06-08 2009-07-16 Genentech Inc Gene expression markers of tumor resistance to her2 inhibitor treatment
US9551033B2 (en) * 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
KR20150055103A (en) 2007-06-12 2015-05-20 에이씨 이뮨 에스.에이. Humanized antibodies to amyloid beta
US7580304B2 (en) * 2007-06-15 2009-08-25 United Memories, Inc. Multiple bus charge sharing
CA2691434A1 (en) 2007-06-21 2008-12-24 Macrogenics, Inc. Covalent diabodies and uses thereof
EP3124046A1 (en) 2007-07-12 2017-02-01 GITR, Inc. Combination therapies employing gitr binding molecules
WO2009012175A1 (en) 2007-07-13 2009-01-22 Ventana Medical Systems, Inc. Antibodies specific for the c-terminal regulatory domain of egfr and their use
EP2657253B1 (en) 2008-01-31 2017-07-19 Genentech, Inc. Anti-CD79b antibodies and immunoconjugates and methods of use
ES2498040T3 (en) 2007-07-27 2014-09-24 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases with humanized anti-beta
CN101952312A (en) 2007-07-31 2011-01-19 米迪缪尼有限公司 Multispecific epitope binding proteins and uses thereof
JP2010536371A (en) 2007-08-21 2010-12-02 ノダリティ,インコーポレイテッド Diagnostic methods, prognosis and treatment methods
JP6035009B2 (en) 2007-08-22 2016-11-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Activatable binding polypeptides and identifying method and use thereof
KR20100080519A (en) 2007-08-30 2010-07-08 큐어디엠 인코포레이티드 Compositions and methods of using proislet peptides and analogs thereof
CA2704064A1 (en) 2007-09-13 2009-03-29 University Of Zurich Humanized antibodies against the .beta.-amyloid peptide
KR101844172B1 (en) 2007-10-02 2018-03-30 테라노스, 인코포레이티드 Modular point-of-care devices and uses thereof
US20090099340A1 (en) * 2007-10-12 2009-04-16 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
US20110212076A1 (en) * 2007-10-15 2011-09-01 King's College London Viral Therapeutic
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
DK2203558T3 (en) 2007-10-18 2016-06-27 Cell Signaling Technology Inc TRANSLOCATION AND mutant ROS kinase IN HUMAN NON-small cell lung carcinoma
CA2704499A1 (en) 2007-11-07 2009-05-14 Genentech, Inc. Methods and compositions for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies
EP2224954B1 (en) 2007-11-07 2014-01-08 Celldex Therapeutics, Inc. Antibodies that bind human dendritic and epithelial cell 205 (dec-205)
JP2011514881A (en) 2007-11-09 2011-05-12 ザ ソルク インスティテュート フォー バイオロジカル スタディーズ Using tam activator as used and immunosuppressive agents tam receptor inhibitor as an immune enhancer
DK2220116T3 (en) 2007-11-12 2012-11-26 Theraclone Sciences Inc Compositions and methods for the therapy and diagnosis of influenza
US20110033476A1 (en) * 2007-11-12 2011-02-10 Theraclone Sciences Inc. Compositions and methods for the therapy and diagnosis of influenza
US20090203043A1 (en) 2007-11-21 2009-08-13 Peter Hornbeck Protein phosphorylation by basophilic serine/threonine kinases in insulin signaling pathways
EP2215123A1 (en) 2007-11-27 2010-08-11 Ablynx N.V. Immunoglobulin constructs
WO2009070642A1 (en) * 2007-11-28 2009-06-04 Medimmune, Llc Protein formulation
US8912149B1 (en) 2007-11-28 2014-12-16 California Institute Of Technology Glycosaminoglycan mimetics
DK2796466T3 (en) 2007-12-07 2018-02-05 Zymogenetics Inc Humanized antibody molecules specific for IL-31
JP5591712B2 (en) 2007-12-14 2014-09-17 ノボ・ノルデイスク・エー/エス Antibody and its use for human nkg2d
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
RU2547939C2 (en) * 2007-12-26 2015-04-10 Биотест Аг Anti-cd138 immunoconjugates and using them
EP2240516B1 (en) * 2007-12-26 2015-07-08 Biotest AG Methods and agents for improving targeting of cd138 expressing tumor cells
US8637026B2 (en) * 2007-12-26 2014-01-28 Vaccinex, Inc. Anti-C35 antibody combination therapies and methods
US8557243B2 (en) * 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
US8557242B2 (en) * 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
US8454960B2 (en) * 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
JP2011509675A (en) 2008-01-18 2011-03-31 メディミューン,エルエルシー Cysteine ​​engineered antibodies for site-specific conjugation
CN101952317B (en) 2008-01-24 2015-07-22 诺沃-诺迪斯克有限公司 Humanized anti-human NKG2A monoclonal antibody
EP2244563A1 (en) 2008-02-01 2010-11-03 Entogenetics, Inc. Methods, compositions, and systems for production of recombinant spider silk polypeptides
EP2262832A4 (en) 2008-02-01 2011-03-09 Ca Minister Health & Welfare Monoclonal antibodies for ebola and marburg viruses
EP2641612A1 (en) 2008-02-05 2013-09-25 Bristol-Myers Squibb Company Alpha 5 - beta 1 antibodies and their uses
US20090220991A1 (en) * 2008-02-29 2009-09-03 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
CA2716799C (en) 2008-03-04 2018-05-22 Pfizer Limited Methods of treating inflammatory pain
US20090226455A1 (en) * 2008-03-06 2009-09-10 Genentech, Inc. Combination therapy with c-met and her antagonists
JP5544309B2 (en) 2008-03-10 2014-07-09 セラクローン サイエンシーズ, インコーポレイテッド Compositions and methods for the treatment and diagnosis of cytomegalovirus infection
KR20110015516A (en) 2008-03-14 2011-02-16 옵셰스트보 스 오그라니첸노이 오트베츠벤노스티유 "이니티움-파름" Antitumoral terpenoid pharmaceutical composition 'abisilin' exhibiting angiogenesis-inhibiting action
EP2604280A3 (en) 2008-03-27 2013-10-16 ZymoGenetics, Inc. Compositions and methods for inhibiting PDGFRBETA and VEGF-A
WO2009126306A3 (en) 2008-04-10 2010-04-22 Cell Signaling Technology, Inc. Compositions and methods for detecting egfr mutations in cancer
KR20110014607A (en) 2008-04-29 2011-02-11 아보트 러보러터리즈 Dual variable domain immunoglobulins and uses thereof
EP2439212B1 (en) 2008-05-02 2016-12-21 Novartis AG Improved fibronectin-based binding molecules and uses thereof
EP2300034B1 (en) 2008-06-02 2018-08-08 Dana-Farber Cancer Institute, Inc. Pharmaceutical composition for use in treating or preventing multiple myeloma or waldenstrom's macroglobulinemia
EP2297209A4 (en) 2008-06-03 2012-08-01 Abbott Lab Dual variable domain immunoglobulins and uses thereof
EP2133433A1 (en) 2008-06-09 2009-12-16 Centre Georges François Leclerc A method for predicting responsiveness to a treatment with an anti-HER2 antibody
WO2009150623A1 (en) 2008-06-13 2009-12-17 Pfizer Inc Treatment of chronic prostatitis
KR20130088908A (en) 2008-06-17 2013-08-08 와이어쓰 엘엘씨 Antineoplastic combinations containing hki-272 and vinorelbine
KR20180085834A (en) 2008-06-25 2018-07-27 에스바테크 - 어 노바티스 컴파니 엘엘씨 Humanization of rabbit antibodies using a universal antibody framework
KR101893010B1 (en) 2008-06-25 2018-08-29 에스바테크 - 어 노바티스 컴파니 엘엘씨 STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα
EP3216803A1 (en) 2008-06-25 2017-09-13 ESBATech, an Alcon Biomedical Research Unit LLC Stable and soluble antibodies inhibiting vegf
WO2010005527A1 (en) 2008-06-30 2010-01-14 Angioblast Systems, Inc. Treatment of eye diseases and excessive neovascularization using a combined therapy
ES2532635T3 (en) 2008-07-15 2015-03-30 Genentech, Inc. Conjugates anthracycline, process for their preparation and their use as antitumor compounds
US8815813B2 (en) * 2008-07-18 2014-08-26 Trinity Therapeutics, Inc. Methods for treating immune-mediated Dengue Fever infections and antibody-dependent enhancement of Dengue Fever infections, including Dengue Hemorrhagic Fever and Dengue Shock Syndrome
US8148088B2 (en) * 2008-07-18 2012-04-03 Abgent Regulation of autophagy pathway phosphorylation and uses thereof
US8790642B2 (en) 2008-08-29 2014-07-29 Genentech, Inc. Cross-reactive and bispecific anti-IL-17A/F antibodies
RU2547596C2 (en) 2008-09-03 2015-04-10 Дженентек, Инк. Polyspecific antibodies
CN102264763B (en) 2008-09-19 2016-04-27 米迪缪尼有限公司 Dll4 directed to antibodies and uses thereof
CA2739357A1 (en) 2008-09-23 2010-04-08 Wyeth Llc Methods for predicting production of activating signals by cross-linked binding proteins
US20110275787A1 (en) 2008-10-01 2011-11-10 Microment AG Cross-species-specific single domain bispecific single chain antibody
JP2012505900A (en) 2008-10-14 2012-03-08 ダイアクス コーポレーション Use of igf-ii / igf-iie binding protein for the treatment and prevention of pulmonary fibrosis associated with systemic scleroderma
EP2347038A4 (en) * 2008-10-14 2013-06-12 Janssen Biotech Inc Methods of humanizing and affinity-maturing antibodies
CA2741798A1 (en) * 2008-10-28 2010-05-06 Shionogi & Co., Ltd. Anti-muc1 antibody
US9393304B2 (en) 2008-10-29 2016-07-19 Ablynx N.V. Formulations of single domain antigen binding molecules
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
CN102482699A (en) 2009-04-29 2012-05-30 詹森生物科技公司 Toll-like receptor 3 antagonists
CN105601742A (en) 2008-10-31 2016-05-25 詹森生物科技公司 Toll-like receptor 3 antagonists
CN102753193A (en) * 2008-10-31 2012-10-24 比奥根艾迪克Ma公司 Light targeting molecules and uses thereof
US8309306B2 (en) * 2008-11-12 2012-11-13 Nodality, Inc. Detection composition
CA2743306A1 (en) 2008-11-12 2010-05-20 Theraclone Sciences, Inc. Human m2e peptide immunogens
JP5933975B2 (en) 2008-11-12 2016-06-15 メディミューン,エルエルシー Antibody preparation
US8211434B2 (en) * 2008-11-26 2012-07-03 Allergan, Inc. KLK-13 antibody inhibitor for treating dry eye
EP2191843A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
EP2191841A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
EP2191842A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
EP2191840A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
US20110287088A1 (en) 2008-12-03 2011-11-24 Research Development Foundation Modulation of olfml-3 mediated angiogenesis
US8401799B2 (en) * 2008-12-05 2013-03-19 Lpath, Inc. Antibody design using anti-lipid antibody crystal structures
WO2010098863A1 (en) * 2009-02-26 2010-09-02 Lpath, Inc. Humanized platelet activating factor antibody design using anti-lipid antibody templates
EP2374001A4 (en) * 2008-12-05 2013-03-13 Lpath Inc Antibody design using anti-lipid antibody crystal structures
KR20180089573A (en) 2008-12-09 2018-08-08 제넨테크, 인크. Anti-pd-l1 antibodies and their use to enhance t-cell function
EP2376117A1 (en) 2008-12-17 2011-10-19 Genentech, Inc. Hepatitis c virus combination therapy
WO2010075249A3 (en) 2008-12-22 2010-10-07 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
EP2379595A2 (en) 2008-12-23 2011-10-26 AstraZeneca AB Targeted binding agents directed to 5 1 and uses thereof
EP3318573A1 (en) * 2008-12-23 2018-05-09 F. Hoffmann-La Roche AG Mmunoglobulin variants with altered binding to protein a
EP2382238A1 (en) 2008-12-31 2011-11-02 Biogen Idec MA Inc. Anti-lymphotoxin antibodies
EP2373339B1 (en) 2009-01-06 2017-04-19 INSERM (Institut National de la Santé et de la Recherche Médicale) A b cell depleting agent for the treatment of atherosclerosis
JP2013516389A (en) 2009-01-06 2013-05-13 ダイアックス コーポレーション Mucositis treatment with kallikrein inhibitor
US20100189651A1 (en) * 2009-01-12 2010-07-29 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
EP2387584A1 (en) 2009-01-14 2011-11-23 IQ Therapeutics BV Combination antibodies for the treatment and prevention of disease caused by bacillus anthracis and related bacteria and their toxins
WO2010087927A2 (en) 2009-02-02 2010-08-05 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
CA2750520C (en) 2009-02-04 2017-12-05 Molecular Innovations Methods for screening candidate agents for modulating prorenin and renin, assays for detecting prorenin, and antibodies used therein
US20100233733A1 (en) * 2009-02-10 2010-09-16 Nodality, Inc., A Delaware Corporation Multiple mechanisms for modulation of the pi3 kinase pathway
WO2010093928A3 (en) 2009-02-12 2010-11-18 Cell Signaling Technology, Inc. Mutant ros expression in human cancer
EP2398860B1 (en) 2009-02-18 2013-11-20 Carnegie Mellon University Quenched dendrimeric dyes for fluorescence detection
EP2398494A4 (en) * 2009-02-23 2015-10-28 Cytomx Therapeutics Inc Proproteins and methods of use thereof
US20100248265A1 (en) * 2009-02-27 2010-09-30 The Salk Institute For Biological Studies Compositions and methods for diagnosis and treatment of cancer
ES2656234T3 (en) 2009-03-17 2018-02-26 Theraclone Sciences, Inc. Neutralizing antibodies to human immunodeficiency virus (HIV)
US8597652B2 (en) 2009-03-20 2013-12-03 Genentech, Inc. Multispecific anti-HER antibodies
US8242248B2 (en) * 2009-03-23 2012-08-14 Nodality, Inc. Kits for multiparametric phospho analysis
JP6051048B2 (en) 2009-03-25 2016-12-21 ジェネンテック, インコーポレイテッド Novel anti-α5β1 antibody and uses thereof
JP5725508B2 (en) 2009-03-25 2015-05-27 国立大学法人東北大学 Lh type bispecific antibody
US8410250B2 (en) 2009-03-25 2013-04-02 Genentech, Inc. Anti-FGFR3 antibodies and methods using same
CN102369215B (en) 2009-04-02 2015-01-21 罗切格利卡特公司 Multispecific antibodies comprising full length antibodies and single chain fab fragments
US20100297127A1 (en) 2009-04-08 2010-11-25 Ghilardi Nico P Use of il-27 antagonists to treat lupus
JP2013525260A (en) * 2009-04-17 2013-06-20 バイオジェン・アイデック・エムエイ・インコーポレイテッド Compositions and methods for treating acute myelogenous leukemia
EP2419446A4 (en) * 2009-04-17 2013-01-23 Lpath Inc Humanized antibody compositions and methods for binding lysophosphatidic acid
JP5836929B2 (en) 2009-04-18 2015-12-24 ジェネンテック, インコーポレイテッド Methods for assessing the responsiveness of the b-cell lymphoma to treatment with an anti-cd40 antibody
WO2010124163A3 (en) * 2009-04-23 2011-03-03 Theraclone Sciences, Inc. Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
WO2010126972A1 (en) 2009-04-29 2010-11-04 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Erg monoclonal antibodies
CN102459628A (en) 2009-05-13 2012-05-16 基酶有限公司 Anti-human cd52 immunoglobulins
EP2432803A2 (en) 2009-05-20 2012-03-28 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
GB0908613D0 (en) * 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
KR20120024794A (en) 2009-05-28 2012-03-14 아브락시스 바이오사이언스, 엘엘씨 Use of 2 anti-sparc antibodies to predict response to chemotherapy
JP5705836B2 (en) 2009-05-29 2015-04-22 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Modulators for her2 signaling gastric cancer patients expressing Her2
WO2010146511A1 (en) 2009-06-17 2010-12-23 Pfizer Limited Treatment of overactive bladder
EP2448593A2 (en) 2009-07-03 2012-05-09 Bionor Immuno AS Hiv related peptides combination or fusion for use in hiv vaccine composition or as diagnostic means
WO2011004899A1 (en) 2009-07-06 2011-01-13 Takeda Pharmaceutical Company Limited Cancerous disease modifying antibodies
WO2011005715A1 (en) 2009-07-07 2011-01-13 Genentech, Inc. Diagnosis and treatment of autoimmune demyelinating diseases
JP2012532846A (en) 2009-07-09 2012-12-20 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Vivo tumor vasculature imaging
US9132202B2 (en) 2009-07-17 2015-09-15 Aaron T. Tabor Compositions and methods for genetic modification of cells having cosmetic function to enhance cosmetic appearance
US20120135464A1 (en) 2009-07-24 2012-05-31 Alexander Alisch Stirrer system
CA2769206A1 (en) 2009-07-31 2011-02-03 Amgen Inc. Polypeptides that bind tissue inhibitor of metalloproteinase type three (timp-3), compositions and methods
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
CN102498129B (en) 2009-07-31 2016-03-02 霍夫曼-拉罗奇有限公司 Use bv8 antagonist or g-csf antagonist inhibits tumor metastasis
US20110039300A1 (en) 2009-08-10 2011-02-17 Robert Bayer Antibodies with enhanced adcc functions
WO2011019679A1 (en) 2009-08-11 2011-02-17 Allergan, Inc. Ccr2 inhibitors for treating conditions of the eye
WO2011020024A3 (en) 2009-08-13 2011-06-23 The Johns Hopkins University Methods of modulating immune function
WO2011019622A1 (en) 2009-08-14 2011-02-17 Genentech, Inc. Cell culture methods to make antibodies with enhanced adcc function
CN102575298A (en) 2009-08-14 2012-07-11 霍夫曼-拉罗奇有限公司 Biological markers for monitoring patient response to VEGF antagonists
US9163086B2 (en) 2009-08-18 2015-10-20 President And Fellows Of Harvard College Methods and compositions for the treatment of proliferative and pathogenic diseases
CN102740884A (en) 2009-08-28 2012-10-17 瑞纳神经科学公司 Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
WO2011028950A1 (en) 2009-09-02 2011-03-10 Genentech, Inc. Mutant smoothened and methods of using the same
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
JP5996429B2 (en) 2009-09-03 2016-09-21 ジェネンテック, インコーポレイテッド Treatment of rheumatoid arthritis, a method for diagnosing and monitoring
JP2013504595A (en) 2009-09-11 2013-02-07 ジェネンテック, インコーポレイテッド The method for identifying patients likely response to anticancer drugs has increased
CN104945509A (en) 2009-09-16 2015-09-30 弗·哈夫曼-拉罗切有限公司 Coiled coil and/or tether containing protein complexes and uses thereof
EP2478362B1 (en) 2009-09-18 2016-05-11 Abraxis BioScience, LLC Use of the sparc microenvironment signature in the treatment of cancer
US8926976B2 (en) * 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
EP2470569A1 (en) 2009-10-13 2012-07-04 Oxford Biotherapeutics Ltd. Antibodies against epha10
JP2013507928A (en) 2009-10-15 2013-03-07 アボット・ラボラトリーズAbbott Laboratories Dual variable domain immunoglobulin and uses thereof
US8759491B2 (en) * 2009-10-19 2014-06-24 Genentech, Inc. Modulators of hepatocyte growth factor activator
RU2539772C2 (en) 2009-10-22 2015-01-27 Дженентек, Инк. Methods and compositions for hepsin modulation of macrophage-stimulating protein
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011056561A1 (en) 2009-10-27 2011-05-12 Beth Israel Deaconess Medical Center Methods and compositions for the generation and use of conformation-specific antibodies
WO2011051327A3 (en) 2009-10-30 2011-06-30 Novartis Ag Small antibody-like single chain proteins
WO2011053763A3 (en) 2009-10-30 2011-10-06 Centocor Ortho Biotech Inc. Il-17a antagonists
JP5956342B2 (en) 2009-11-03 2016-07-27 シティ・オブ・ホープCity of Hope Truncated epidermal growth factor receptor for the transduced T cells selected (EGFRt)
EP2496257A4 (en) 2009-11-05 2013-02-27 Cephalon Australia Pty Ltd Treatment of cancer involving mutated kras or braf genes
JP5818003B2 (en) 2009-11-18 2015-11-18 国立大学法人東北大学 High functional variants of humanized anti egfr antibody variable region
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
RU2577977C2 (en) 2009-12-09 2016-03-20 Байер Фарма Акциенгезельшафт Anti-c4,4a antibodies and their use
JP5818805B2 (en) 2009-12-11 2015-11-18 ジェネンテック, インコーポレイテッド Anti vegf-c antibodies and methods of use thereof
US8937159B2 (en) 2009-12-16 2015-01-20 Abbvie Biotherapeutics Inc. Anti-HER2 antibodies and their uses
US8771685B2 (en) 2009-12-23 2014-07-08 F. Hoffmann-La Roche Ag Anti-BV8 antibodies and uses thereof
WO2011079283A1 (en) * 2009-12-23 2011-06-30 Bioalliance C.V. Anti-epcam antibodies that induce apoptosis of cancer cells and methods using same
US9315581B2 (en) 2009-12-23 2016-04-19 A Vipep Pty Limited Immuno-conjugates and methods for producing them
WO2011082187A1 (en) 2009-12-30 2011-07-07 Genentech, Inc. Methods for modulating a pdgf-aa mediated biological response
DK2521568T3 (en) 2010-01-06 2018-11-19 Dyax Corp Plasmakallikreinbindende proteins
WO2011088193A3 (en) 2010-01-13 2012-01-05 New Jersey Institute Of Technology Fluorophore chelated lanthanide luminiscent probes with improved quantum efficiency
JP2013517464A (en) 2010-01-15 2013-05-16 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Methods for the diagnosis and treatment of cutaneous t-cell lymphoma
US8362210B2 (en) 2010-01-19 2013-01-29 Xencor, Inc. Antibody variants with enhanced complement activity
JP5947727B2 (en) 2010-01-20 2016-07-06 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. Immune regulation by anti ilt5 antibodies and ilt5 binding antibody fragment
EP2525813B1 (en) 2010-01-20 2017-01-04 Merck Sharp & Dohme Corp. Anti-ilt5 antibodies and ilt5-binding antibody fragments
WO2011097527A3 (en) 2010-02-04 2012-01-26 Xencor, Inc. Immunoprotection of therapeutic moieties using enhanced fc regions
US20110189178A1 (en) * 2010-02-04 2011-08-04 Xencor, Inc. Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions
CN102933231B (en) 2010-02-10 2015-07-29 伊缪诺金公司 Cd20 antibody and uses thereof
WO2011103242A1 (en) 2010-02-18 2011-08-25 Genentech, Inc. Neuregulin antagonists and use thereof in treating cancer
US20110200595A1 (en) 2010-02-18 2011-08-18 Roche Glycart TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR
CN102167742B (en) * 2010-02-25 2014-05-14 上海百迈博制药有限公司 Human monoclonal antibody against HER2, preparation method and purpose thereof
US20110212088A1 (en) * 2010-02-26 2011-09-01 Sabbadini Roger A Anti-paf antibodies
ES2638521T3 (en) 2010-03-05 2017-10-23 The Johns Hopkins University Compositions and methods for antibodies and fusion proteins directed against targets immunomodulatory
GB201003701D0 (en) 2010-03-05 2010-04-21 Cilian Ag System for the expression of a protein
CN102858362A (en) 2010-03-11 2013-01-02 阿布拉西斯生物科学有限责任公司 SPARC angiogenic domain and methods of use
CN104998269A (en) 2010-03-22 2015-10-28 弗·哈夫曼-拉罗切有限公司 Compositions and methods useful for stabilizing protein-containing formulations
US8846041B2 (en) 2010-03-24 2014-09-30 Genentech, Inc. Anti-LRP6 antibodies
JP6060073B2 (en) 2010-04-08 2017-01-11 ジェイエヌ バイオサイエンシーズ エルエルシー Antibody against Cd122
CN103154027B (en) 2010-04-09 2016-06-29 重症监护诊断股份有限公司 St-2 soluble human antibody and analysis
WO2011130434A9 (en) 2010-04-13 2012-07-19 Celldex Therapeutics Inc. Antibodies that bind human cd27 and uses thereof
WO2011130580A1 (en) 2010-04-15 2011-10-20 Alper Biotech, Llc Monoclonal antibodies against her2 antigens, and uses therefor
WO2011133931A1 (en) 2010-04-22 2011-10-27 Genentech, Inc. Use of il-27 antagonists for treating inflammatory bowel disease
WO2011137245A3 (en) * 2010-04-30 2012-08-02 Esperance Pharmaceuticals, Inc. Lytic-peptide-her2/neu (human epidermal growth factor receptor 2) ligand conjugates and methods of use
CA2794864A1 (en) 2010-05-03 2011-11-10 Genentech, Inc. Compositions and methods useful for reducing the viscosity of protein-containing formulations
US9403855B2 (en) 2010-05-10 2016-08-02 Academia Sinica Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
WO2011146568A8 (en) 2010-05-19 2012-06-28 F. Hoffmann-La Roche Ag Predicting response to a her inhibitor
WO2011145085A3 (en) 2010-05-21 2012-03-01 Procognia (Israel) Ltd Novel antibodies and methods of use for the treatment and diagnosis of cancer
WO2011150079A1 (en) 2010-05-25 2011-12-01 Carnegie Mellon University Targeted probes of cellular physiology
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
WO2011153224A3 (en) 2010-06-02 2012-05-31 F. Hoffmann-La Roche Ag Diagnostic methods and compositions for treatment of cancer
JP2013530166A (en) 2010-06-03 2013-07-25 アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー Use of sparc microenvironment trace signature in the treatment of cancer
US20110311527A1 (en) 2010-06-16 2011-12-22 Allergan, Inc. IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
CA2812556A1 (en) 2010-09-23 2012-03-29 Xue-Ping Wang Colon and pancreas cancer peptidomimetics
WO2011161119A1 (en) 2010-06-22 2011-12-29 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof
EP2585476A4 (en) 2010-06-22 2014-01-22 Neogenix Oncology Inc Colon and pancreas cancer specific antigens and antibodies
WO2011161189A1 (en) 2010-06-24 2011-12-29 F. Hoffmann-La Roche Ag Anti-hepsin antibodies and methods of use
EP2591004A1 (en) 2010-07-09 2013-05-15 F.Hoffmann-La Roche Ag Anti-neuropilin antibodies and methods of use
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
WO2012010582A1 (en) 2010-07-21 2012-01-26 Roche Glycart Ag Anti-cxcr5 antibodies and methods of use
JP5953303B2 (en) 2010-07-29 2016-07-20 ゼンコア インコーポレイテッド Antibodies having isoelectric points that have been modified
EP2598126A2 (en) 2010-07-30 2013-06-05 Saint Louis University Methods of treating pain
CN107903321A (en) 2010-07-30 2018-04-13 诺华有限公司 Fibronectin cradle molecules and libraries thereof
CA2806855A1 (en) 2010-08-03 2012-02-09 F. Hoffmann - La Roche Ag Chronic lymphocytic leukemia (cll) biomarkers
EP2601212A1 (en) 2010-08-04 2013-06-12 Cizzle Biotechnology Limited Methods and compounds for the diagnosis and treatment of
US20120101108A1 (en) 2010-08-06 2012-04-26 Cell Signaling Technology, Inc. Anaplastic Lymphoma Kinase In Kidney Cancer
EP2603237A4 (en) 2010-08-12 2014-05-21 Theraclone Sciences Inc Anti-hemagglutinin antibody compositions and methods of use thereof
JP2012034668A (en) 2010-08-12 2012-02-23 Tohoku Univ Fragment of humanized anti-egfr antibody substituted-lysine variable region, and use thereof
CA2806640A1 (en) 2010-08-13 2012-02-16 Roche Glycart Ag Anti-tenascin-c a2 antibodies and methods of use
CN104474546A (en) 2010-08-13 2015-04-01 弗·哈夫曼-拉罗切有限公司 Antibodies to il-1beta and il-18, for treatment of disease
EP2420250A1 (en) 2010-08-13 2012-02-22 Universitätsklinikum Münster Anti-Syndecan-4 antibodies
CN105440134A (en) 2010-08-16 2016-03-30 安姆根公司 Antibody of combination of muscle amicine, compound and method
WO2012022682A1 (en) 2010-08-17 2012-02-23 F. Hoffmann-La Roche Ag Anti-human igg1 antibody
WO2012027494A1 (en) 2010-08-24 2012-03-01 Regents Of The University Of Minnesota Bispecific targeting reagents
US20130129619A1 (en) 2010-08-24 2013-05-23 H. Lee Moffitt Cancer Center And Research Institute, Inc. Molecular Imaging of Cancer Cells In Vivo
CN103068846B9 (en) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 Bispecific antibody containing disulfide-stabilized Fv fragment
KR101603001B1 (en) 2010-08-25 2016-03-11 에프. 호프만-라 로슈 아게 Antibodies against il-18r1 and uses thereof
US9046513B2 (en) 2010-08-26 2015-06-02 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
CA2809837A1 (en) 2010-08-31 2012-03-08 Theraclone Sciences, Inc. Human immunodeficiency virus (hiv)-neutralizing antibodies
US9228023B2 (en) 2010-10-01 2016-01-05 Oxford Biotherapeutics Ltd. Anti-ROR1 antibodies and methods of use for treatment of cancer
WO2012061129A1 (en) 2010-10-25 2012-05-10 Genentech, Inc Treatment of gastrointestinal inflammation and psoriasis a
JP5847188B2 (en) 2010-10-25 2016-01-20 バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. By associating a difference of sVCAM and / or sMAdCAM level, a method for determining the difference between the alpha-4 integrin activity
KR20130139975A (en) 2010-11-04 2013-12-23 베링거 인겔하임 인터내셔날 게엠베하 Anti-il-23 antibodies
EP2638070B1 (en) 2010-11-10 2016-10-19 F.Hoffmann-La Roche Ag Methods and compositions for neural disease immunotherapy
ES2544608T3 (en) 2010-11-17 2015-09-02 Genentech, Inc. Conjugates of the antibody and alaninyl-maytansinol
US20130245233A1 (en) 2010-11-24 2013-09-19 Ming Lei Multispecific Molecules
US8728473B2 (en) 2010-12-01 2014-05-20 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
WO2012075173A3 (en) 2010-12-01 2013-01-03 Board Of Regents The University Of Texas System Compositions and method for deimmunization of proteins
WO2012084829A1 (en) 2010-12-21 2012-06-28 F. Hoffmann-La Roche Ag Isoform enriched antibody preparation and method for obtaining it
ES2524897T3 (en) 2010-12-21 2014-12-15 F. Hoffmann-La Roche Ag Characterization of chromatography equipment
EP2655419A1 (en) 2010-12-22 2013-10-30 F.Hoffmann-La Roche Ag Anti-pcsk9 antibodies and methods of use
CN103384681B (en) 2010-12-23 2018-05-18 霍夫曼-拉罗奇有限公司 Binding agent
WO2012085111A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
WO2012092539A3 (en) 2010-12-31 2012-10-04 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
US20120171195A1 (en) 2011-01-03 2012-07-05 Ravindranath Mepur H Anti-hla-e antibodies, therapeutic immunomodulatory antibodies to human hla-e heavy chain, useful as ivig mimetics and methods of their use
JP2014502607A (en) 2011-01-03 2014-02-03 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Pharmaceutical compositions of the complex of digoxigenin are conjugated with anti-dig antibodies and peptides
WO2012103240A3 (en) 2011-01-25 2012-10-26 Eleven Biotherapeutics, Inc. Chimeric il-1 receptor type i agonists and antagonists
CA2825894A1 (en) 2011-02-02 2012-08-09 Amgen Inc. Prognosis of cancer using a circulating biomarker
CA2825064A1 (en) 2011-02-04 2012-08-09 Genentech, Inc. Fc variants and methods for their production
KR20140019344A (en) 2011-02-08 2014-02-14 메디뮨 엘엘씨 Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use
CA2827301A1 (en) 2011-02-14 2012-08-23 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
EP2680884B1 (en) 2011-02-28 2018-01-17 F.Hoffmann-La Roche Ag Biological markers and methods for predicting response to b-cell antagonists
WO2012119989A3 (en) 2011-03-04 2012-11-08 Oryzon Genomics, S.A. Antibodies against cadmi for the diagnosis and treatment of cancer
WO2012122512A1 (en) 2011-03-10 2012-09-13 Hco Antibody, Inc. Recombinant production of mixtures of single chain antibodies
CN103619876A (en) 2011-03-10 2014-03-05 Hco抗体股份有限公司 Bispecific three-chain antibody-like molecules
JP2014511836A (en) 2011-03-25 2014-05-19 グレンマーク ファーマシューティカルズ, エセ.アー. Heterodimer immunoglobulin
EP2696898A4 (en) 2011-04-07 2014-10-01 Univ Emory Compositions comprising saccharide binding moieties and methods for targeted therapy
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US8951522B2 (en) 2011-04-08 2015-02-10 University Of Leicester Methods for treating conditions associated with MASP-2 dependent complement activation
CA3019531A1 (en) 2011-04-19 2012-10-26 Pfizer Inc. Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
CN103608040B (en) 2011-04-20 2017-03-01 米迪缪尼有限公司 B7-h1 binding antibodies and other molecules of pd-1
EP2699597B1 (en) 2011-04-21 2016-06-01 Garvan Institute of Medical Research Modified variable domain molecules and methods for producing and using them b
WO2013101771A3 (en) 2011-12-30 2013-10-10 Genentech, Inc. Compositions and method for treating autoimmune diseases
WO2012146630A1 (en) 2011-04-29 2012-11-01 F. Hoffmann-La Roche Ag N-terminal acylated polypeptides, methods for their production and uses thereof
US20120282249A1 (en) 2011-05-02 2012-11-08 Millennium Pharmaceuticals, Inc. Formulation for anti-alpha4beta7 antibody
CA2834776A1 (en) 2011-05-03 2012-11-08 Genentech, Inc. Therapeutic apo2l/trail polypeptides and death receptor agonist antibodies
EP2704739B1 (en) 2011-05-06 2017-07-12 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services Recombinant immunotoxin targeting mesothelin
RU2638806C2 (en) 2011-05-12 2017-12-15 Дженентек, Инк. Lc-ms/ms method for multiple reactions monitoring to identify therapeutic antibodies in animal species using framework signature peptides
WO2012158948A1 (en) 2011-05-17 2012-11-22 The Rockefeller University Human immunodeficiency virus neutralizing antibodies adn methods of use thereof
CN108373502A (en) 2011-05-20 2018-08-07 奥尔德生物控股有限责任公司 Anti-cgrp compositions and use thereof
CN104080804B (en) 2011-05-21 2017-06-09 宏观基因有限公司 Deimmunized serum binding domain and uses extended serum half-life
WO2012167039A1 (en) 2011-06-02 2012-12-06 Dyax Corp. Fc RECEPTOR BINDING PROTEINS
JP6305919B2 (en) 2011-06-06 2018-04-04 プロセナ バイオサイエンシーズ リミテッド Mcam antagonists and methods of treatment
US20140141020A1 (en) * 2011-06-14 2014-05-22 Mayo Foundation For Medical Education And Research Anti-cd3 therapies
US8623666B2 (en) 2011-06-15 2014-01-07 Hoffmann-La Roche Inc. Method for detecting erythropoietin (EPO) receptor using anti-human EPO receptor antibodies
CN103649125A (en) 2011-06-22 2014-03-19 霍夫曼-拉罗奇有限公司 Removal of target cells by circulating virus-specific cytotoxic t-cells using MHC class I comprising complexes
EP2537933A1 (en) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
EP2726508B1 (en) 2011-06-28 2017-08-09 Oxford BioTherapeutics Ltd Antibodies to adp-ribosyl cyclase 2
CA2835242A1 (en) 2011-06-30 2013-01-03 Genentech, Inc. Anti-c-met antibody formulations
US9120858B2 (en) 2011-07-22 2015-09-01 The Research Foundation Of State University Of New York Antibodies to the B12-transcobalamin receptor
WO2013015821A1 (en) 2011-07-22 2013-01-31 The Research Foundation Of State University Of New York Antibodies to the b12-transcobalamin receptor
WO2013022855A1 (en) 2011-08-05 2013-02-14 Xencor, Inc. Antibodies with modified isoelectric points and immunofiltering
EP2739310B1 (en) 2011-08-05 2018-04-18 Research Development Foundation Improved methods and compositions for modulation of olfml3 mediated angiogenesis
CN103890007A (en) 2011-08-17 2014-06-25 霍夫曼-拉罗奇有限公司 Neuregulin antibodies and uses thereof
CA2842481A1 (en) 2011-08-17 2013-02-21 Genentech, Inc. Inhibition of angiogenesis in refractory tumors
KR20140054303A (en) 2011-08-19 2014-05-08 리제너론 파아마슈티컬스, 인크. Anti-tie2 antibodies and uses thereof
CN103889452B (en) 2011-08-23 2017-11-03 罗切格利卡特公司 Of t cell activation antigen and a tumor antigen specific bispecific antibodies and methods of use
CN103890006A (en) 2011-08-23 2014-06-25 罗切格利卡特公司 Anti-mcsp antibodies
JP6339015B2 (en) 2011-08-23 2018-06-06 ロシュ グリクアート アーゲー Bispecific t cell activation antigen binding molecule
US20130078250A1 (en) 2011-08-23 2013-03-28 Oliver Ast Bispecific t cell activating antigen binding molecules
KR101723273B1 (en) 2011-08-23 2017-04-04 로슈 글리카트 아게 Fc-free antibodies comprising two fab fragments and methods of use
CA2843158A1 (en) 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
US8822651B2 (en) 2011-08-30 2014-09-02 Theraclone Sciences, Inc. Human rhinovirus (HRV) antibodies
JP6297490B2 (en) 2011-08-31 2018-03-20 ジェネンテック, インコーポレイテッド Diagnostic marker
RU2014109395A (en) 2011-09-15 2015-10-20 Дженентек, Инк. Methods for the stimulation of differentiation
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
CN103930111A (en) 2011-09-19 2014-07-16 霍夫曼-拉罗奇有限公司 Combination treatments comprising C-MET antagonists and B-RAF antagonists
CA2849705A1 (en) 2011-09-23 2013-03-28 Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa Modified albumin-binding domains and uses thereof to improve pharmacokinetics
US8475739B2 (en) 2011-09-25 2013-07-02 Theranos, Inc. Systems and methods for fluid handling
US8840838B2 (en) 2011-09-25 2014-09-23 Theranos, Inc. Centrifuge configurations
US10012664B2 (en) 2011-09-25 2018-07-03 Theranos Ip Company, Llc Systems and methods for fluid and component handling
US9250229B2 (en) 2011-09-25 2016-02-02 Theranos, Inc. Systems and methods for multi-analysis
US9664702B2 (en) 2011-09-25 2017-05-30 Theranos, Inc. Fluid handling apparatus and configurations
US9268915B2 (en) 2011-09-25 2016-02-23 Theranos, Inc. Systems and methods for diagnosis or treatment
US9632102B2 (en) 2011-09-25 2017-04-25 Theranos, Inc. Systems and methods for multi-purpose analysis
US9619627B2 (en) 2011-09-25 2017-04-11 Theranos, Inc. Systems and methods for collecting and transmitting assay results
US8435738B2 (en) 2011-09-25 2013-05-07 Theranos, Inc. Systems and methods for multi-analysis
US20130089562A1 (en) 2011-10-05 2013-04-11 Genenthech, Inc. Methods of treating liver conditions using notch2 antagonists
KR20130036993A (en) * 2011-10-05 2013-04-15 삼성전자주식회사 Antibodies specifically binding to epitope in sema domain of c-met
WO2013054320A1 (en) 2011-10-11 2013-04-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
WO2013056248A2 (en) 2011-10-13 2013-04-18 The Regents Of The University Of California Treatment of breast cancer with companion diagnostic
WO2013055998A1 (en) 2011-10-14 2013-04-18 Genentech, Inc. ANTI-HtrA1 ANTIBODIES AND METHODS OF USE
KR20170023195A (en) 2011-10-14 2017-03-02 제넨테크, 인크. Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab
US9358250B2 (en) 2011-10-15 2016-06-07 Genentech, Inc. Methods of using SCD1 antagonists
WO2013059531A1 (en) 2011-10-20 2013-04-25 Genentech, Inc. Anti-gcgr antibodies and uses thereof
WO2013057290A1 (en) 2011-10-21 2013-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) A m-dc8+ monocyte depleting agent for the prevention or the treatment of a condition associated with a chronic hyperactivation of the immune system
WO2013063229A1 (en) 2011-10-25 2013-05-02 The Regents Of The University Of Michigan Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells
EP2771031B1 (en) 2011-10-28 2018-04-18 Prothena Biosciences Limited Humanized antibodies that recognize alpha-synuclein
WO2013063419A3 (en) 2011-10-28 2015-08-06 The Trustees Of The University Of Pennsylvania A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
KR20140097205A (en) 2011-10-28 2014-08-06 제넨테크, 인크. Therapeutic combinations and methods of treating melanoma
EP2773651A4 (en) 2011-11-03 2015-08-12 Univ Pennsylvania Isolated b7-h4 specific compositions and methods of use thereof
US20140322216A1 (en) 2011-11-08 2014-10-30 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
KR20140101738A (en) 2011-11-16 2014-08-20 베링거 인겔하임 인터내셔날 게엠베하 Anti il-36r antibodies
CN104302669A (en) 2011-11-23 2015-01-21 伊格尼卡生物治疗公司 Anti-CD98 antibodies and methods of use thereof
CA2856297A1 (en) 2011-11-23 2013-05-30 Medimmune, Llc Binding molecules specific for her3 and uses thereof
WO2013079174A1 (en) 2011-11-28 2013-06-06 Merck Patent Gmbh Anti-pd-l1 antibodies and uses thereof
US20130195870A1 (en) 2011-11-30 2013-08-01 Genentech, Inc. ERBB3 Mutations In Cancer
US20140335084A1 (en) 2011-12-06 2014-11-13 Hoffmann-La Roche Inc. Antibody formulation
US9376715B2 (en) 2011-12-09 2016-06-28 Roche Molecular Systems, Inc Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
EP2791171A1 (en) 2011-12-16 2014-10-22 Synthon Biopharmaceuticals B.V. EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED
CA2853955A1 (en) 2011-12-22 2013-06-27 F. Hoffmann-La Roche Ag Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides
US20160208284A1 (en) 2011-12-22 2016-07-21 Hoffmann-La Roche Inc. Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides
EP2793944A4 (en) 2011-12-23 2015-09-02 Nicholas B Lydon Immunoglobulins and variants directed against pathogenic microbes
WO2013096812A1 (en) 2011-12-23 2013-06-27 Genentech, Inc. Articles of manufacture and methods for co-administration of antibodies
US9717803B2 (en) 2011-12-23 2017-08-01 Innate Pharma Enzymatic conjugation of polypeptides
EP2794660A2 (en) 2011-12-23 2014-10-29 Phenoquest AG Antibodies for the treatment and diagnosis of affective and anxiety disorders
WO2013096791A1 (en) 2011-12-23 2013-06-27 Genentech, Inc. Process for making high concentration protein formulations
US9988439B2 (en) 2011-12-23 2018-06-05 Nicholas B. Lydon Immunoglobulins and variants directed against pathogenic microbes
WO2013093809A1 (en) 2011-12-23 2013-06-27 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
US20150011431A1 (en) 2012-01-09 2015-01-08 The Scripps Research Institute Humanized antibodies
US20130177574A1 (en) 2012-01-11 2013-07-11 Paul I. Terasaki Foundation Laboratory ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE
WO2013104798A1 (en) 2012-01-12 2013-07-18 Cemm - Center For Molecular Medicine Of The Austrian Academy Of Sciences Modulators of immune responses
CN104168920A (en) 2012-01-18 2014-11-26 霍夫曼-拉罗奇有限公司 Methods of using FGF19 modulators
EP2804629A1 (en) 2012-01-18 2014-11-26 Genentech, Inc. Anti-lrp5 antibodies and methods of use
JP6342333B2 (en) 2012-01-27 2018-06-13 プロセナ バイオサイエンシーズ リミテッド Humanized antibodies that recognize α- synuclein
WO2013113641A1 (en) 2012-01-31 2013-08-08 Roche Glycart Ag Use of nkp46 as a predictive biomarker for cancer treatment with adcc- enhanced antibodies
CN104379601A (en) 2012-02-03 2015-02-25 霍夫曼-拉罗奇有限公司 Bispecific antibody molecules with antigen-transfected t-cells and their use in medicine
CA2861124A1 (en) 2012-02-10 2013-08-15 Genentech, Inc. Single-chain antibodies and other heteromultimers
WO2013120056A1 (en) 2012-02-11 2013-08-15 Genentech, Inc. R-spondin translocations and methods using the same
CN104125852B9 (en) 2012-02-15 2017-05-17 弗·哈夫曼-拉罗切有限公司 Based Fc- receptor affinity chromatography
WO2013123114A3 (en) 2012-02-16 2013-12-05 Santarus, Inc. Anti-vla1 (cd49a) antibody pharmaceutical compositions
CN104220458B (en) * 2012-02-24 2018-08-14 阿特根公司 There are binding motif containing cysteine ​​residues modified antibody, which modified antibody-containing modified - drug conjugate and a method of manufacturing thereof
CA2864177A1 (en) 2012-03-01 2013-09-06 Amgen Research (Munich) Gmbh Prolonged half-life albumin-binding protein fused bispecific antibodies
KR20140130455A (en) 2012-03-02 2014-11-10 로슈 글리카트 아게 Predicitive biomarker for cancer treatment with adcc enhanced antibodies
CN104379602B (en) 2012-03-08 2017-05-03 哈洛齐梅公司 Anti-EGFR antibodies and use conditional activity
US20150098988A1 (en) 2012-03-13 2015-04-09 Hoffmann-La Roche Inc. Combination therapy for the treatment of ovarian cancer
EP2638916A1 (en) 2012-03-16 2013-09-18 Covagen AG Novel binding molecules with antitumoral activity
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
CN104394879A (en) 2012-03-27 2015-03-04 株式会社绿十字 Epitopes of epidermal growth factor receptor surface antigen and use thereof
EP2830661A4 (en) 2012-03-30 2016-05-18 Hoffmann La Roche Diagnostic methods and compositions for treatment of cancer
WO2013150518A1 (en) 2012-04-01 2013-10-10 Rappaport Family Institute For Research In The Medical Sciences Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
EP3336181A1 (en) 2012-04-18 2018-06-20 Cell Signaling Technology, Inc. Egfr and ros1 in cancer
US9056910B2 (en) 2012-05-01 2015-06-16 Genentech, Inc. Anti-PMEL17 antibodies and immunoconjugates
EP2847219A1 (en) 2012-05-07 2015-03-18 Amgen Inc. Anti-erythropoietin antibodies
KR101505157B1 (en) 2012-05-08 2015-03-24 주식회사 종근당 Anti-ErbB2 Antibody Variants
WO2013170191A1 (en) 2012-05-11 2013-11-14 Genentech, Inc. Methods of using antagonists of nad biosynthesis from nicotinamide
EP2850106A4 (en) * 2012-05-18 2016-04-20 Scott&White Healthcare Bispecific scfv immunofusion (bif)
WO2013182660A1 (en) 2012-06-06 2013-12-12 Bionor Immuno As Hiv vaccine
US9617334B2 (en) 2012-06-06 2017-04-11 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof
WO2013188855A1 (en) 2012-06-15 2013-12-19 Genentech, Inc. Anti-pcsk9 antibodies, formulations, dosing, and methods of use
US20140051834A1 (en) 2012-06-21 2014-02-20 Hoffmann-La Roche, Inc. Incretin Receptor Ligand Polypeptide Fc-Region Fusion Polypeptides And Conjugates With Altered Fc-Effector Function
KR20150023906A (en) 2012-06-27 2015-03-05 에프. 호프만-라 로슈 아게 Method for the selection and production of tailor-made, selective and multi-specific therapeutic molecules comprising at least two different targeting entities and uses thereof
WO2014004549A3 (en) 2012-06-27 2014-03-13 Amgen Inc. Anti-mesothelin binding proteins
DK2869848T3 (en) 2012-07-04 2016-11-21 F Hoffmann-La Roche Ag Covalent BOUND ANTIGEN-ANTIBODY CONJUGATES
EP3339328A1 (en) 2012-07-04 2018-06-27 F. Hoffmann-La Roche AG Anti-biotin antibodies and methods of use
WO2014008391A1 (en) 2012-07-05 2014-01-09 Genentech, Inc. Expression and secretion system
US20160168247A1 (en) 2013-07-05 2016-06-16 Genmab A/S Humanized or chimeric cd3 antibodies
KR20150030753A (en) 2012-07-09 2015-03-20 제넨테크, 인크. Immunoconjugates comprising anti-cd79b antibodies
CA2874856A1 (en) 2012-07-09 2014-01-16 Genentech, Inc. Immunoconjugates comprising anti-cd79b antibodies
EP2872894A2 (en) 2012-07-13 2015-05-20 Innate Pharma Screening of conjugated antibodies
DK2877493T3 (en) 2012-07-25 2018-06-14 Celldex Therapeutics Inc Anti-kit antibodies and uses thereof
CA2876096A1 (en) 2012-08-02 2014-02-06 Petra Rueger Method for producing soluble fcr as fc-fusion with inert immunoglobulin fc-region and uses thereof
KR20150034765A (en) 2012-08-07 2015-04-03 로슈 글리카트 아게 Composition comprising two antibodies engineered to have reduced and increased effector function
WO2014026033A9 (en) 2012-08-08 2014-03-06 University Of Florida Research Foundation, Inc. Cross-reactive t cell epitopes of hiv, siv, and fiv for vaccines in humans and cats
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
FR2994390B1 (en) 2012-08-10 2014-08-15 Adocia Method for lowering the viscosity of protein solutions at high concentration
WO2014028939A3 (en) 2012-08-17 2014-04-10 California Institute Of Technology Targeting phosphofructokinase and its glycosylation form for cancer
WO2014031498A1 (en) 2012-08-18 2014-02-27 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
JP6211084B2 (en) 2012-08-21 2017-10-11 アカデミア シニカAcademia Sinica Benzo cyclooctene Chin compounds and use thereof
KR20150076172A (en) 2012-09-25 2015-07-06 그렌마크 파머수티칼스 에스. 아. Purification of Hetero-dimeric Immunoglobulins
EP2904106A4 (en) 2012-10-01 2016-05-11 Univ Pennsylvania Compositions and methods for targeting stromal cells for the treatment of cancer
US9598489B2 (en) 2012-10-05 2017-03-21 The Trustees Of The Univeristy Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
KR20150063447A (en) 2012-10-08 2015-06-09 프로테나 바이오사이언시즈 리미티드 Antibodies recognizing alpha-synuclein
KR20150064068A (en) 2012-10-08 2015-06-10 로슈 글리카트 아게 FC-FREE ANTIBODIES COMPRISING TWO Fab-FRAGMENTS AND METHODS OF USE
EP2906591A1 (en) 2012-10-15 2015-08-19 Universität Zürich Bispecific her2 ligands for cancer therapy
EP2719706A1 (en) 2012-10-15 2014-04-16 Universität Zürich Bispecific HER2 ligands for cancer therapy
US9309318B2 (en) 2012-10-17 2016-04-12 Amgen, Inc. Compositions relating to anti-IL-21 receptor antibodies
EP2912064A1 (en) 2012-10-24 2015-09-02 Research Development Foundation Jam-c antibodies and methods for treatment of cancer
EP2914633A4 (en) * 2012-10-30 2016-07-06 Esperance Pharmaceuticals Inc Antibody/drug conjugates and methods of use
JP6374392B2 (en) 2012-11-05 2018-08-15 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド Xbp1, CD138 and cs1 peptides, pharmaceutical compositions containing the peptides and methods of using such peptides and compositions
WO2014072482A1 (en) 2012-11-09 2014-05-15 Innate Pharma Recognition tags for tgase-mediated conjugation
WO2014078268A8 (en) 2012-11-13 2015-01-22 Genentech, Inc. Anti-hemagglutinin antibodies and methods of use
US9810670B2 (en) 2012-11-15 2017-11-07 Genentech, Inc. Ionic strength-mediated pH gradient ion exchange chromatography
US20140161790A1 (en) 2012-11-19 2014-06-12 Xencor, Inc. Engineered immunoglobulins with extended in vivo half-life
US10131682B2 (en) 2012-11-24 2018-11-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules
CN104870019A (en) 2012-11-27 2015-08-26 阿特根公司 Composition for stabilizing fusion protein in which protein and fc domain are fused
EP2928495A4 (en) 2012-12-07 2016-05-11 Sanofi Sa Compositions comprising anti-cd38 antibodies and lenalidomide
CN105452295A (en) 2012-12-10 2016-03-30 比奥根Ma公司 Anti-blood dendritic cell antigen 2 antibodies and uses thereof
CA2894879A1 (en) 2012-12-19 2014-06-26 Amplimmune, Inc. B7-h4 specific antibodies, and compositions and methods of use thereof
KR20150100848A (en) 2012-12-27 2015-09-02 사노피 Anti-lamp1 antibodies and antibody drug conjugates, and uses thereof
EP3336104A1 (en) 2012-12-28 2018-06-20 Precision Biologics, Inc. Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
WO2014107739A1 (en) 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Antibodies against pcsk9
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
KR20150129685A (en) 2013-03-15 2015-11-20 젠코어 인코포레이티드 Heterodimeric proteins
US9738722B2 (en) 2013-01-15 2017-08-22 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
WO2014114595A1 (en) 2013-01-23 2014-07-31 Roche Glycart Ag Predictive biomarker for cancer treatment with adcc-enhanced antibodies
WO2014116749A1 (en) 2013-01-23 2014-07-31 Genentech, Inc. Anti-hcv antibodies and methods of using thereof
EP2951199A4 (en) 2013-01-31 2016-07-20 Univ Jefferson Fusion proteins for modulating regulatory and effector t cells
JP6367836B2 (en) 2013-02-07 2018-08-01 ザ ジェネラル ホスピタル コーポレイション The method of proliferation or depletion T regulatory cells
KR20150119206A (en) 2013-02-15 2015-10-23 가부시키가이샤 페르세우스 프로테오믹스 Anti-cdh3 humanized antibody, drug conjugate thereof, and utilization of same
US9810704B2 (en) 2013-02-18 2017-11-07 Theranos, Inc. Systems and methods for multi-analysis
CN105358576A (en) 2013-02-20 2016-02-24 诺华股份有限公司 Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor
EP2958942A1 (en) 2013-02-20 2015-12-30 Novartis AG Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
KR20150118159A (en) 2013-02-22 2015-10-21 에프. 호프만-라 로슈 아게 Methods of treating cancer and preventing drug resistance
CA2896359A1 (en) 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
CA2896259A1 (en) 2013-02-26 2014-09-04 Roche Glycart Ag Anti-mcsp antibodies
WO2014131712A1 (en) 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
CA2902263A1 (en) 2013-03-06 2014-09-12 Genentech, Inc. Methods of treating and preventing cancer drug resistance
KR20150131203A (en) 2013-03-13 2015-11-24 메디뮨 리미티드 Pyrrolobenzodiazepines and conjugates thereof
KR20150127199A (en) 2013-03-14 2015-11-16 제넨테크, 인크. Anti-b7-h4 antibodies and immunoconjugates
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
CN105307683A (en) 2013-03-14 2016-02-03 基因泰克公司 Methods of treating cancer and preventing cancer drug resistance
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
WO2014150877A3 (en) 2013-03-15 2014-11-27 Ac Immune S.A. Anti-tau antibodies and methods of use
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
KR20150131269A (en) 2013-03-15 2015-11-24 제넨테크, 인크. Biomarkers and methods of treating pd-1 and pd-l1 related conditions
US10035860B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
US10035859B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
US20140283157A1 (en) 2013-03-15 2014-09-18 Diadexus, Inc. Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
US9446105B2 (en) 2013-03-15 2016-09-20 The Trustees Of The University Of Pennsylvania Chimeric antigen receptor specific for folate receptor β
US9260527B2 (en) 2013-03-15 2016-02-16 Sdix, Llc Anti-human CXCR4 antibodies and methods of making same
CN105143265A (en) 2013-03-15 2015-12-09 豪夫迈·罗氏有限公司 Anti-crth2 antibodies and their use
EP2976361B1 (en) 2013-03-18 2018-07-18 BiocerOX Products B.V. Humanized anti-cd134 (ox40) antibodies and uses thereof
JP6316937B2 (en) 2013-04-03 2018-04-25 ロシュ グリクアート アーゲー Fap and dr5 specific bispecific antibodies, specific antibodies as well as methods of use dr5
US20140314741A1 (en) * 2013-04-18 2014-10-23 Developmen Center For Biotechnology Human Antibody against Interleukin-20 and Treatment for Inflammatory Diseases
CN105164158A (en) 2013-04-29 2015-12-16 豪夫迈·罗氏有限公司 Fcrn-binding abolished ANTI-IGF-1R antibodies and their use in the treatment of vascular eye diseases
KR101453462B1 (en) 2013-05-16 2014-10-23 앱클론(주) Antibodies Capable of Binding Specifically to HER2
CN106414489A (en) 2013-05-24 2017-02-15 米迪缪尼有限公司 Anti-b7-h5 antibodies and their uses
JP2016532433A (en) 2013-05-31 2016-10-20 ジェネンテック, インコーポレイテッド Anti-cell wall teichoic acid antibodies and conjugates
US10100123B2 (en) 2013-06-06 2018-10-16 Pierre Fabre Medicament Anti-C10orf54 antibodies and uses thereof
EP3008210A4 (en) 2013-06-13 2017-05-17 University Of South Australia Methods for detecting prostate cancer
CA2915311A1 (en) 2013-06-14 2014-12-18 Bayer Pharma Aktiengesellschaft Anti-tweakr antibodies and uses thereof
EP3010547A1 (en) 2013-06-20 2016-04-27 Innate Pharma Enzymatic conjugation of polypeptides
KR20160042871A (en) 2013-06-21 2016-04-20 이나뜨 파르마, 에스.아. Enzymatic conjugation of polypeptides
US10086054B2 (en) 2013-06-26 2018-10-02 Academia Sinica RM2 antigens and use thereof
EP3013347A4 (en) 2013-06-27 2017-01-18 Academia Sinica Glycan conjugates and use thereof
US20150079074A1 (en) 2013-07-04 2015-03-19 Neotope Biosciences Limited Antibody Formulations And Methods
EP3016683A4 (en) 2013-07-05 2017-02-22 University of Washington through its Center for Commercialization Soluble mic neutralizing monoclonal antibody for treating cancer
WO2015004632A1 (en) 2013-07-12 2015-01-15 Neotope Biosciences Limited Antibodies that recognize iapp
WO2015004633A1 (en) 2013-07-12 2015-01-15 Neotope Biosciences Limited Antibodies that recognize islet-amyloid polypeptide (iapp)
US20160159928A1 (en) 2013-07-18 2016-06-09 Fabrus, Inc. Humanized antibodies with ultralong complementary determining regions
WO2015017146A3 (en) 2013-07-18 2015-10-01 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
WO2015007337A1 (en) 2013-07-19 2015-01-22 Bionor Immuno As Method for the vaccination against hiv
WO2015015448A3 (en) 2013-07-31 2015-04-30 Rinat Neuroscience Corp. Engineered polypeptide conjugates using transglutaminase
KR20160030578A (en) 2013-08-01 2016-03-18 파이브 프라임 테라퓨틱스, 인크. Afucosylated anti-fgfr2iiib antibodies
US9770461B2 (en) 2013-08-02 2017-09-26 California Institute Of Technology Tailored glycopolymers as anticoagulant heparin mimetics
WO2015095212A1 (en) 2013-12-16 2015-06-25 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
CA2918139A1 (en) 2013-08-12 2015-02-19 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
EP3036320A1 (en) 2013-08-19 2016-06-29 Biogen MA Inc. Control of protein glycosylation by culture medium supplementation and cell culture process parameters
WO2015025054A1 (en) 2013-08-22 2015-02-26 Medizinische Universität Wien Dye-specific antibodies for prestained molecular weight markers and methods producing the same
EP3041484A4 (en) 2013-09-06 2017-04-12 Academia Sinica HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS WITH ALTERED GLYCOSYL GROUPS
CN104418947A (en) 2013-09-11 2015-03-18 香港大学 Anti-her2 and anti-igf-ir bi-specific antibodies and uses thereof
WO2015038811A3 (en) 2013-09-11 2015-07-23 Arsia Therapeutics, Inc. Liquid protein formulations containing ionic liquids
EP3044236A2 (en) 2013-09-12 2016-07-20 Halozyme, Inc. Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
CN104193828B (en) * 2013-09-12 2017-04-05 北京韩美药品有限公司 Her2 vegfr while blocking the signal path and a recombinant fusion protein
CN105814078A (en) 2013-10-11 2016-07-27 豪夫迈·罗氏有限公司 Nsp4 inhibitors and methods of use
CN105744954A (en) 2013-10-18 2016-07-06 豪夫迈·罗氏有限公司 Anti-rsp02 and/or anti-rsp03 antibodies and their uses
CN104628846A (en) 2013-11-06 2015-05-20 上海中信国健药业股份有限公司 Purification method of recombinant protein
US20160279238A1 (en) 2013-11-19 2016-09-29 Prothena Biosciences Limited Monitoring immunotherapy of lewy body disease from constipation symptoms
KR20160086942A (en) 2013-11-20 2016-07-20 리제너론 파아마슈티컬스, 인크. Aplnr modulators and uses thereof
CN105916519A (en) 2013-12-09 2016-08-31 阿拉科斯公司 Anti-siglec-8 antibodies and methods of use thereof
WO2015087187A1 (en) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anti-sclerostin antibodies
CN105814084A (en) 2013-12-13 2016-07-27 基因泰克公司 Anti-cd33 antibodies and immunoconjugates
WO2015095404A3 (en) 2013-12-17 2015-08-13 Genentech, Inc. Methods of treating cancers using pd-1 axis binding antagonists and taxanes
RU2016129247A (en) 2013-12-20 2018-01-25 Дженентек, Инк. Bispecific antibodies
EP3083933A1 (en) 2013-12-20 2016-10-26 Biogen MA Inc. Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
KR20160105880A (en) 2014-01-03 2016-09-07 에프. 호프만-라 로슈 아게 Covalently linked polypeptide toxin-antibody conjugates
RU2016129894A3 (en) 2014-01-03 2018-07-23
US20160333083A1 (en) 2014-01-14 2016-11-17 The Medical College Of Wisconsin, Inc. Targeting clptm1l for treatment and prevention of cancer
EP3094647A1 (en) 2014-01-15 2016-11-23 F. Hoffmann-La Roche AG Fc-region variants with modified fcrn- and maintained protein a-binding properties
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US20160340406A1 (en) 2014-01-21 2016-11-24 Novartis Ag Enhanced antigen presenting ability of rna car t cells by co-introduction of costimulatory molecules
JP5998289B2 (en) 2014-01-31 2016-09-28 第一三共株式会社 Anti her2 antibody - drug conjugates
US9840543B2 (en) 2014-01-31 2017-12-12 Boehringer Ingelheim International Gmbh Anti-BAFF antibodies
DK3102197T3 (en) 2014-02-04 2018-11-19 Genentech Inc Smoothened mutant and methods of use thereof
EP3102231A1 (en) 2014-02-08 2016-12-14 F.Hoffmann-La Roche Ag Methods of treating alzheimer's disease
KR20150097304A (en) 2014-02-18 2015-08-26 삼성전자주식회사 Anti-EGFR/Anti-HER2 Bispecific Antibodies With Anti-EGFR DARPins
CA2937556A1 (en) 2014-02-21 2015-08-27 Genentech, Inc. Anti-il-13/il-17 bispecific antibodies and uses thereof
WO2015130416A9 (en) 2014-02-25 2016-10-06 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
WO2015136472A1 (en) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg4-5
WO2015136471A1 (en) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg1-3
KR20160127825A (en) 2014-03-12 2016-11-04 프로테나 바이오사이언시즈 리미티드 Anti-mcam antibodies and associated methods of use
KR20170052526A (en) 2014-03-13 2017-05-12 프로테나 바이오사이언시즈 리미티드 Combination treatment for multiple sclerosis
EP3116999A1 (en) 2014-03-14 2017-01-18 F.Hoffmann-La Roche Ag Methods and compositions for secretion of heterologous polypeptides
WO2015142675A8 (en) 2014-03-15 2016-10-20 Novartis Ag Treatment of cancer using chimeric antigen receptor
WO2015140591A1 (en) 2014-03-21 2015-09-24 Nordlandssykehuset Hf Anti-cd14 antibodies and uses thereof
WO2015143409A1 (en) 2014-03-21 2015-09-24 Labrys Biologics, Inc. Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
EP3122900A1 (en) 2014-03-24 2017-02-01 F.Hoffmann-La Roche Ag Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
US20170174764A1 (en) 2014-03-27 2017-06-22 Yeda Research And Development Co. Ltd. T-cell receptor cdr3 peptides and antibodies
WO2015148915A9 (en) 2014-03-27 2016-12-22 Academia Sinica Reactive labelling compounds and uses thereof
US20170174777A1 (en) 2014-04-08 2017-06-22 Prothena Bioscience Limited Blood-Brain Barrier Shuttles Containing Antibodies Recognizing Alpha-Synuclein
EP3131584A1 (en) 2014-04-16 2017-02-22 Biocon Limited Stable protein formulations comprising a molar excess of sorbitol
WO2015164615A1 (en) 2014-04-24 2015-10-29 University Of Oslo Anti-gluten antibodies and uses thereof
US20170043033A1 (en) 2014-04-25 2017-02-16 Rinat Neuroscience Corp. Antibody-drug conjugates with high drug loading
CA2946662A1 (en) 2014-05-22 2015-11-26 Genentech, Inc. Anti-gpc3 antibodies and immunoconjugates
CA2944717A1 (en) 2014-05-23 2015-11-26 Genentech, Inc. Mit biomarkers and methods using the same
JP2017523131A (en) 2014-05-27 2017-08-17 アカデミア シニカAcademia Sinica Anti her2 glycoengineered antibody group and their use
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
WO2015191715A1 (en) 2014-06-11 2015-12-17 Genentech, Inc. Anti-lgr5 antibodies and uses thereof
CN107073121A (en) 2014-06-13 2017-08-18 基因泰克公司 Methods of treating and preventing cancer drug resistance
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
JP2017520255A (en) 2014-07-03 2017-07-27 ジェネンテック, インコーポレイテッド Polypeptide expression system
US10132818B2 (en) 2014-07-08 2018-11-20 New York University Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy
CA2954868A1 (en) 2014-07-11 2016-01-14 Genentech, Inc. Anti-pd-l1 antibodies and diagnostic uses thereof
EP3169801A1 (en) 2014-07-14 2017-05-24 F.Hoffmann-La Roche Ag Diagnostic methods and compositions for treatment of glioblastoma
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US20170211055A1 (en) 2014-07-21 2017-07-27 Novartis Ag Sortase synthesized chimeric antigen receptors
WO2016014530A1 (en) 2014-07-21 2016-01-28 Novartis Ag Combinations of low, immune enhancing. doses of mtor inhibitors and cars
CA2956178A1 (en) 2014-07-24 2016-01-28 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
WO2016014775A9 (en) 2014-07-24 2016-11-17 Boehringer Ingelheim International Gmbh Biomarkers useful in the treatment of il-23a related diseases
WO2016016442A1 (en) 2014-08-01 2016-02-04 INSERM (Institut National de la Santé et de la Recherche Médicale) An anti-cd45rc antibody for use as drug
WO2016025880A1 (en) 2014-08-14 2016-02-18 Novartis Ag Treatment of cancer using gfr alpha-4 chimeric antigen receptor
EP2985294A1 (en) 2014-08-14 2016-02-17 Deutsches Krebsforschungszentrum Recombinant antibody molecule and its use for target cell restricted T cell activation
US20180140714A1 (en) 2014-08-28 2018-05-24 Pfizer Inc. Stability-modulating linkers for use with antibody drug conjugates
US20170275374A1 (en) 2014-09-04 2017-09-28 Cellectis Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy
WO2016037985A1 (en) 2014-09-08 2016-03-17 Ruprecht-Karls-Universität Heidelberg Construct for the delivery of a molecule into the cytoplasm of a cell
US20160075772A1 (en) 2014-09-12 2016-03-17 Regeneron Pharmaceuticals, Inc. Treatment of Fibrodysplasia Ossificans Progressiva
EP3191518A1 (en) 2014-09-12 2017-07-19 Genentech, Inc. Anti-b7-h4 antibodies and immunoconjugates
US20160074528A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
JP2017531620A (en) 2014-09-12 2017-10-26 ジェネンテック, インコーポレイテッド Cysteine ​​engineered antibodies and conjugates
CA2959689A1 (en) 2014-09-17 2016-03-24 Genentech, Inc. Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
US10080790B2 (en) 2014-09-19 2018-09-25 The Regents Of The University Of Michigan Staphylococcus aureus materials and methods
KR20170063671A (en) 2014-09-23 2017-06-08 리제너론 파마슈티칼스 인코포레이티드 Anti-il-25 antibodies and uses thereof
US9921230B2 (en) 2014-10-08 2018-03-20 Rhode Island Hospital Methods for diagnosis and treatment of concussion or brain injury
CN107074938A (en) 2014-10-16 2017-08-18 豪夫迈·罗氏有限公司 Anti-alpha-synuclein antibodies and methods of use
US20170327861A1 (en) 2014-10-17 2017-11-16 Biogen Ma Inc. Copper Supplementation for Control of Glycosylation in Mammalian Cell Culture Process
US9821059B2 (en) 2014-10-17 2017-11-21 Alteogen Inc. Composition for stabilizing protein and pharmaceutical formulation comprising the same
US10040844B2 (en) 2014-10-22 2018-08-07 The Regents Of The University Of California Proteolytic release of cell surface antigens for phage biopanning
US20170327786A1 (en) 2014-10-31 2017-11-16 Biogen Ma Inc. Hypotaurine, GABA, Beta-Alanine, and Choline for Control of Waste Byproduct Accumulation in Mammalian Cell Culture Process
KR20170086540A (en) 2014-11-03 2017-07-26 제넨테크, 인크. Assays for detecting t cell immune subsets and methods of use thereof
CN107075548A (en) 2014-11-05 2017-08-18 基因泰克公司 Methods of producing two chain proteins in bacteria
KR20170075793A (en) 2014-11-05 2017-07-03 제넨테크, 인크. Methods of producing two chain proteins in bacteria
WO2016073157A1 (en) 2014-11-06 2016-05-12 Genentech, Inc. Anti-ang2 antibodies and methods of use thereof
US20160152720A1 (en) 2014-11-06 2016-06-02 Genentech, Inc. Combination therapy comprising ox40 binding agonists and tigit inhibitors
WO2016077369A1 (en) 2014-11-10 2016-05-19 Genentech, Inc. Animal model for nephropathy and agents for treating the same
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
JP2017535264A (en) 2014-11-12 2017-11-30 ライナット ニューロサイエンス コーポレイション Inhibitory chimeric antigen receptor
KR20170089881A (en) 2014-11-17 2017-08-04 리제너론 파아마슈티컬스, 인크. Methods for tumor treatment using cd3xcd20 bispecific antibody
WO2016081384A1 (en) 2014-11-17 2016-05-26 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
EP3221362A1 (en) 2014-11-19 2017-09-27 F.Hoffmann-La Roche Ag Anti-transferrin receptor antibodies and methods of use
US20170362339A1 (en) 2014-11-19 2017-12-21 Genentech, Inc. Antibodies against bace1 and use thereof for neural disease immunotherapy
JP2018505652A (en) 2014-11-19 2018-03-01 ジェネンテック, インコーポレイテッド Anti-transferrin receptor / anti bace1 multispecific antibodies and methods of use
CA2966964A1 (en) 2014-11-19 2016-05-26 Michal Novak Humanized tau antibodies in alzheimer's disease
CN108025046A (en) 2015-05-08 2018-05-11 森科股份有限公司 Heterodimeric antibodies that bind cd3 and tumor antigens
US20160355608A1 (en) 2014-11-26 2016-12-08 Xencor, Inc. Heterodimeric antibodies that bind cd3 and tumor antigens
JP2017537105A (en) 2014-11-26 2017-12-14 ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. Vedolizumab for the treatment of Crohn's disease with fistula
CA2968878A1 (en) 2014-11-26 2016-06-02 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd38
US20160152732A1 (en) * 2014-11-28 2016-06-02 The Israel Institute of Biological Research (IIBR) Antibodies directed to ricin toxin
EP3029067A1 (en) 2014-12-01 2016-06-08 Deutsches Krebsforschungszentrum Use of blocking-reagents for reducing unspecific T cell-activation
US20170269092A1 (en) 2014-12-02 2017-09-21 Cemm - Forschungszentrum Fuer Molekulare Medizin Gmbh Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies
WO2016090038A1 (en) 2014-12-03 2016-06-09 Genentech, Inc. Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
JP2018507166A (en) 2014-12-03 2018-03-15 ジェネンテック, インコーポレイテッド Anti staphylococcus aureus antibody rifamycin conjugates and the use thereof
WO2016094881A3 (en) 2014-12-11 2016-08-18 Abbvie Inc. Lrp-8 binding proteins
WO2016094837A3 (en) 2014-12-11 2016-08-11 Igenica Biotherapeutics, Inc. Anti-c10orf54 antibodies and uses thereof
KR20170099963A (en) 2014-12-19 2017-09-01 레제네상스 비.브이. Antibodies that bind human c6 and uses thereof
US20160200815A1 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
EP3247723A1 (en) 2015-01-22 2017-11-29 Chugai Seiyaku Kabushiki Kaisha A combination of two or more anti-c5 antibodies and methods of use
KR20180041152A (en) 2015-08-11 2018-04-23 셀렉티스 The Cd38 antigen cd38 gene targeting and cellular immunotherapy for the operation in order to inactivate
CN107407677A (en) 2015-01-28 2017-11-28 豪夫迈·罗氏有限公司 Gene expression markers and treatment of multiple sclerosis
WO2018007923A3 (en) 2016-07-02 2018-03-15 Prothena Biosciences Limited Anti-transthyretin antibodies
WO2018007922A3 (en) 2016-07-02 2018-02-15 Prothena Biosciences Limited Anti-transthyretin antibodies
WO2018007924A3 (en) 2016-07-02 2018-03-01 Prothena Biosciences Limited Anti-transthyretin antibodies
US20180044424A1 (en) 2015-02-02 2018-02-15 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
EP3253784A1 (en) 2015-02-04 2017-12-13 Genentech, Inc. Mutant smoothened and methods of using the same
KR20170110129A (en) 2015-02-05 2017-10-10 추가이 세이야쿠 가부시키가이샤 Ion concentration-dependent antibody comprising an antigen binding domain, Fc domain variants dogs, antibody binding to IL-8, and their use
US20160237399A1 (en) 2015-02-18 2016-08-18 Biogen Ma Inc. Control of Protein Glycosylation by Culture Medium Supplementation and Cell Culture Process Parameters
CA2976593A1 (en) 2015-02-23 2016-09-01 Seagull Therapeutics Sas Non-natural semaphorins 3 and their medical use
EP3262072A1 (en) 2015-02-26 2018-01-03 H. Hoffnabb-La Roche Ag Integrin beta7 antagonists and methods of treating crohn's disease
US20170037131A1 (en) 2015-03-05 2017-02-09 Matthew Bernett Modulation of t cells with bispecific antibodies and fc fusions
WO2016144824A1 (en) 2015-03-06 2016-09-15 Genentech, Inc. Ultrapurified dsba and dsbc and methods of making and using the same
WO2016149276A1 (en) 2015-03-16 2016-09-22 Genentech, Inc. Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases
EP3069734A1 (en) 2015-03-17 2016-09-21 Exiris S.r.l. Cryptophycin-based antibody-drug conjugates with novel self-immolative linkers
WO2016146833A1 (en) 2015-03-19 2016-09-22 F. Hoffmann-La Roche Ag Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
US20180282411A1 (en) 2015-03-30 2018-10-04 Regeneron Pharmaceuticals, Inc. Heavy Chain Constant Regions with Reduced Binding to Fc Gamma Receptors
JP2018512145A (en) 2015-04-03 2018-05-17 ユーリカ セラピューティックス, インコーポレイテッド Constructs and uses thereof to target Afp peptide / mhc complex
CN107709364A (en) 2015-04-07 2018-02-16 豪夫迈·罗氏有限公司 Antigen binding complex having agonistic activity and methods of use
US20180140602A1 (en) 2015-04-07 2018-05-24 Novartis Ag Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
CA2981751A1 (en) 2015-04-08 2016-10-13 Novartis Ag Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car)- expressing cell
WO2016166139A1 (en) 2015-04-14 2016-10-20 Eberhard Karls Universität Tübingen Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells
JP2018512422A (en) 2015-04-14 2018-05-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング A method of treating a disease
WO2016166360A1 (en) 2015-04-17 2016-10-20 Bayer Pharma Aktiengesellschaft Bispecific antibody constructs for cdh3 and cd3
CA2982246A1 (en) 2015-04-17 2016-10-20 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
EP3286211A1 (en) 2015-04-23 2018-02-28 Novartis AG Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
CN107810197A (en) 2015-04-24 2018-03-16 豪夫迈·罗氏有限公司 Methods of identifying bacteria comprising binding polypeptides
EP3288976A1 (en) 2015-04-29 2018-03-07 Regeneron Pharmaceuticals, Inc. Treatment of fibrodysplasia ossificans progressiva
EP3288584A2 (en) 2015-04-30 2018-03-07 President and Fellows of Harvard College Anti-ap2 antibodies and antigen binding agents to treat metabolic disorders
EP3288981A1 (en) 2015-05-01 2018-03-07 Genentech, Inc. Masked anti-cd3 antibodies and methods of use
JP2018515603A (en) 2015-05-04 2018-06-14 ビオノル・イムノ・アクシェセルスカプBionor Immuno AS The dosage regimen for Hiv vaccine
WO2016179194A1 (en) 2015-05-04 2016-11-10 Jounce Therapeutics, Inc. Lilra3 and method of using the same
US20160326234A1 (en) * 2015-05-07 2016-11-10 Andrew Hiatt Monoclonal antibody cocktails for treatment of ebola infections
EP3303400A1 (en) 2015-05-28 2018-04-11 Genentech, Inc. Cell-based assay for detecting anti-cd3 homodimers
CA2984003A1 (en) 2015-05-29 2016-12-08 Genentech, Inc. Therapeutic and diagnostic methods for cancer
JP2018520658A (en) 2015-05-29 2018-08-02 ジェネンテック, インコーポレイテッド Humanized Anti-Ebola virus glycoprotein antibodies and uses thereof
KR20180010259A (en) 2015-05-30 2018-01-30 몰레큘러 템플레이츠, 인코퍼레이션. De-immunization of a Shiga toxin subunit scaffold and cells comprising the same-targeting molecules
WO2016196373A8 (en) 2015-05-30 2017-11-30 Genentech, Inc. Methods of treating her2-positive locally advanced or previously untreated metastatic breast cancer
EP3302552A1 (en) 2015-06-02 2018-04-11 H. Hoffnabb-La Roche Ag Compositions and methods for using anti-il-34 antibodies to treat neurological diseases
WO2016196726A9 (en) 2015-06-05 2017-04-13 Genentech, Inc. Anti-tau antibodies and methods of use
CA2985483A1 (en) 2015-06-08 2016-12-15 Genentech, Inc. Methods of treating cancer using anti-ox40 antibodies
KR20180025888A (en) 2015-06-08 2018-03-09 제넨테크, 인크. A method for treating cancer using the antibodies and wherein -ox40 pd-1 antagonists shaft coupling
CN108064246A (en) 2015-06-15 2018-05-22 基因泰克公司 Antibodies and immunoconjugates
WO2016204966A1 (en) 2015-06-16 2016-12-22 Genentech, Inc. Anti-cd3 antibodies and methods of use
CN107847568A (en) 2015-06-16 2018-03-27 豪夫迈·罗氏有限公司 Anti-Cll-1 antibodies and methods of use
WO2016205531A3 (en) 2015-06-17 2017-02-09 Genentech, Inc. Anti-her2 antibodies and methods of use
CA2990394A1 (en) 2015-06-23 2016-12-29 Bayer Pharma Aktiengesellschaft Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-tweakr-antibodies
US20180230193A1 (en) 2015-08-07 2018-08-16 Andreas Loew Treatment of cancer using chimeric cd3 receptor proteins
US20170192017A1 (en) 2015-08-25 2017-07-06 Prothena Biosciences Limited Methods For Detecting Phosphorylated Alpha-Synuclein
EP3341415A1 (en) 2015-08-28 2018-07-04 H. Hoffnabb-La Roche Ag Anti-hypusine antibodies and uses thereof
CN107949573A (en) 2015-09-01 2018-04-20 艾吉纳斯公司 Anti-PD-1 antibodies and methods of use thereof
JP2018530540A (en) 2015-09-16 2018-10-18 プロセナ バイオサイエンシーズ リミテッド Giant cell arteritis, use of anti mcam antibodies for the treatment or prevention of polymyalgia rheumatica or Takayasu arteritis
WO2017046774A3 (en) 2015-09-16 2017-05-04 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
CA2999369A1 (en) 2015-09-22 2017-03-30 Spring Bioscience Corporation Anti-ox40 antibodies and diagnostic uses thereof
CA2999385A1 (en) 2015-09-23 2017-03-30 Regeneron Pharmaceuticals, Inc. Optimized anti-cd3 bispecific antibodies and uses thereof
EP3353203A2 (en) 2015-09-23 2018-08-01 H. Hoffnabb-La Roche Ag Optimized variants of anti-vegf antibodies
US20170096485A1 (en) 2015-10-02 2017-04-06 Hoffmann-La Roche Inc. Bispecific t cell activating antigen binding molecules
WO2017055388A3 (en) 2015-10-02 2017-05-11 F. Hoffmann-La Roche Ag Bispecific t cell activating antigen binding molecules
US20170247454A1 (en) 2015-10-02 2017-08-31 Hoffmann-La Roche Inc. Anti-pd1 antibodies and methods of use
WO2017055392A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules
WO2017055385A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xgd2 bispecific t cell activating antigen binding molecules
US10058613B2 (en) 2015-10-02 2018-08-28 Genentech, Inc. Pyrrolobenzodiazepine antibody drug conjugates and methods of use
EP3356406A1 (en) 2015-10-02 2018-08-08 H. Hoffnabb-La Roche Ag Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
EP3150636A1 (en) 2015-10-02 2017-04-05 F. Hoffmann-La Roche AG Tetravalent multispecific antibodies
CN108602887A (en) 2015-10-02 2018-09-28 豪夫迈·罗氏有限公司 Bispecific antibodies to costimulatory receptor specificity of tnf
US20180282410A1 (en) 2015-10-02 2018-10-04 Hoffmann-La Roche Inc. Anti-cd3xrob04 bispecific t cell activating antigen binding molecules
JP2018533929A (en) 2015-10-02 2018-11-22 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Bispecific anti-CD19 × CD3 T cell activation antigen binding molecule
WO2017055393A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules
WO2017062682A8 (en) 2015-10-06 2018-02-01 Genentech, Inc. Method for treating multiple sclerosis
KR20180054877A (en) 2015-10-07 2018-05-24 에프. 호프만-라 로슈 아게 Ball stimulation bispecific antibodies with four whether for tnf receptor
EP3362100A1 (en) 2015-10-16 2018-08-22 Genentech, Inc. Hindered disulfide drug conjugates
WO2017068511A1 (en) 2015-10-20 2017-04-27 Genentech, Inc. Calicheamicin-antibody-drug conjugates and methods of use
GB201518675D0 (en) 2015-10-21 2015-12-02 Cellcap Technologies Ltd Detection of structural forms of proteins
EP3365372A1 (en) 2015-10-22 2018-08-29 Jounce Therapeutics, Inc. Gene signatures for determining icos expression
EP3184547A1 (en) 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg antibodies and methods of use
JP2018534297A (en) 2015-10-29 2018-11-22 ノバルティス アーゲー Antibody conjugate comprising a toll-like receptor agonist
WO2017072210A1 (en) 2015-10-29 2017-05-04 F. Hoffmann-La Roche Ag Anti-variant fc-region antibodies and methods of use
US20170145112A1 (en) 2015-10-30 2017-05-25 Genentech, Inc. Anti-factor d antibodies and conjugates
WO2017079165A1 (en) 2015-11-02 2017-05-11 Genentech, Inc. Methods of making fucosylated and afucosylated forms of a protein
WO2017076492A1 (en) 2015-11-03 2017-05-11 Merck Patent Gmbh Bi-specific antibodies for enhanced tumor selectivity and inhibition and uses thereof
WO2017079215A1 (en) 2015-11-03 2017-05-11 Glycomimetics, Inc. Methods and compositions for the production of monoclonal antibodies, hematopoietic stem cells, and methods of using the same
CA3004530A1 (en) 2015-11-07 2017-05-11 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
WO2017079768A1 (en) 2015-11-08 2017-05-11 Genentech, Inc. Methods of screening for multispecific antibodies
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
EP3377533A2 (en) 2015-11-19 2018-09-26 Sutro Biopharma, Inc. Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
CN106729743A (en) 2015-11-23 2017-05-31 四川科伦博泰生物医药股份有限公司 Anti-ErbB2 antibody-drug conjugate, composition, preparation method and application of anti-ErbB2 antibody-drug conjugate
KR20180081606A (en) 2015-11-23 2018-07-16 파이브 프라임 테라퓨틱스, 인크. Exclusive of, or used in combination with immune stimulants, fgfr2 inhibitors in the treatment of cancer
CA2949032A1 (en) 2015-11-30 2017-05-30 Pfizer Inc. Site specific her2 antibody drug conjugates
EP3383911A1 (en) 2015-12-02 2018-10-10 STCube & Co. Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
EP3178848A1 (en) 2015-12-09 2017-06-14 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
EP3252078A1 (en) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
CN108602893A (en) 2015-12-11 2018-09-28 戴埃克斯有限公司 Plasma kallikrein inhibitors and the treatment of hereditary angioedema attack
CA3007644A1 (en) 2015-12-11 2017-06-15 Regeneron Pharmaceuticals, Inc. Methods for reducing or preventing growth of tumors resistant to egfr and/or erbb3 blockade
WO2017106684A3 (en) 2015-12-17 2017-08-10 Janssen Biotech, Inc. Antibodies specifically binding hla-dr and their uses
CN105646704A (en) * 2015-12-28 2016-06-08 广西医科大学 Anti-p185<erbB2> human-mouse chimeric antibody ChAb26, mammary gland specific expression vectors, transgenic FVB mouse, and preparation method of transgenic FVB mouse
CN107531795A (en) 2016-01-05 2018-01-02 江苏恒瑞医药股份有限公司 Pcsk9 antibody, antigen-binding fragment thereof, and medical uses thereof
EP3192810A1 (en) 2016-01-14 2017-07-19 Deutsches Krebsforschungszentrum Psma binding antibody and uses thereof
EP3405489A1 (en) 2016-01-20 2018-11-28 Genentech, Inc. High dose treatments for alzheimer's disease
EP3405492A1 (en) 2016-01-21 2018-11-28 Novartis AG Multispecific molecules targeting cll-1
EP3408671A1 (en) 2016-01-25 2018-12-05 H. Hoffnabb-La Roche Ag Methods for assaying t-cell dependent bispecific antibodies
KR20180104106A (en) 2016-01-27 2018-09-19 서트로 바이오파마, 인크. A method of utilizing the anti-CD74 antibody conjugates, compositions, and anti-CD74 antibody conjugate comprising an anti-CD74 antibody conjugate
WO2017147542A3 (en) 2016-02-26 2017-10-12 Regeneron Pharmaceuticals, Inc. Optimized transglutaminase site-specific antibody conjugation
CA3015528A1 (en) 2016-02-29 2017-09-08 Genentech, Inc. Therapeutic and diagnostic methods for cancer
WO2017149538A1 (en) 2016-03-01 2017-09-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human poliovirus receptor (pvr)
WO2017149513A1 (en) 2016-03-03 2017-09-08 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
KR20180118175A (en) 2016-03-04 2018-10-30 노파르티스 아게 Multi-chimeric antigen receptor cell and thus the use according to (car) expressing the molecule
EP3216458A1 (en) 2016-03-07 2017-09-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Modified vascular endothelial growth factor a (vegf-a) and its medical use
WO2017153953A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
WO2017153955A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
WO2017160700A1 (en) 2016-03-14 2017-09-21 Millennium Pharmaceuticals, Inc. Methods of treating or preventing graft versus host disease
KR20180120706A (en) 2016-03-14 2018-11-06 밀레니엄 파머슈티컬스 인코퍼레이티드 How to prevent graft-versus-host disease
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
CN108884170A (en) 2016-03-22 2018-11-23 豪夫迈·罗氏有限公司 The protease-activated cell bispecific molecule t
WO2017165683A1 (en) 2016-03-23 2017-09-28 Novartis Ag Cell secreted minibodies and uses thereof
WO2017162555A1 (en) 2016-03-24 2017-09-28 Bayer Pharma Aktiengesellschaft Radio-pharmaceutical complexes
CN108700598A (en) 2016-03-25 2018-10-23 豪夫迈·罗氏有限公司 Multiplexing total antibody and conjugated drug antibody assay quantization
CA3017608A1 (en) 2016-03-29 2017-10-05 Stcube, Inc. Dual function antibodies specific to glycosylated pd-l1 and methods of use thereof
EP3231813A1 (en) 2016-03-29 2017-10-18 F. Hoffmann-La Roche AG Trimeric costimulatory tnf family ligand-containing antigen binding molecules
WO2017172517A1 (en) 2016-03-29 2017-10-05 Stcube & Co., Inc. Methods for selecting antibodies that specifically bind glycosylated immune checkpoint proteins
WO2017180864A1 (en) 2016-04-14 2017-10-19 Genentech, Inc. Anti-rspo3 antibodies and methods of use
WO2017181152A3 (en) 2016-04-15 2018-02-15 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof
CA3020718A1 (en) 2016-04-15 2017-10-19 Genentech, Inc. Methods for monitoring and treating cancer
US20170320959A1 (en) 2016-04-15 2017-11-09 Alpine Immune Sciences, Inc. Icos ligand variant immunomodulatory proteins and uses thereof
WO2017181119A3 (en) 2016-04-15 2018-01-04 Novartis Ag Compositions and methods for selective protein expression
US20170298126A1 (en) 2016-04-15 2017-10-19 Boehringer Ingelheim International Gmbh Methods of treating inflammatory diseases
US20180066053A1 (en) 2016-04-18 2018-03-08 Celldex Therapeutics, Inc. Agonistic antibodies that bind human cd40 and uses thereof
WO2017182427A1 (en) 2016-04-19 2017-10-26 Amgen Research (Munich) Gmbh Administration of a bispecific construct binding to cd33 and cd3 for use in a method for the treatment of myeloid leukemia
WO2017186950A1 (en) 2016-04-28 2017-11-02 Biomunex Pharmaceuticals Bispecific antibodies targeting egfr and her2
WO2017191559A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Tau immunotherapy
CA3022765A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Antibodies recognizing tau
EP3241847A1 (en) * 2016-05-06 2017-11-08 MAB Discovery GmbH Her-2 binding antibodies
WO2017194554A1 (en) 2016-05-10 2017-11-16 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combinations therapies for the treatment of cancer
WO2017194442A1 (en) 2016-05-11 2017-11-16 F. Hoffmann-La Roche Ag Antigen binding molecules comprising a tnf family ligand trimer and a tenascin binding moiety
EP3243836A1 (en) 2016-05-11 2017-11-15 F. Hoffmann-La Roche AG C-terminally fused tnf family ligand trimer-containing antigen binding molecules
WO2017194441A1 (en) 2016-05-11 2017-11-16 F. Hoffmann-La Roche Ag Modified anti-tenascin antibodies and methods of use
EP3243832A1 (en) 2016-05-13 2017-11-15 F. Hoffmann-La Roche AG Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
WO2017201036A1 (en) 2016-05-17 2017-11-23 Genentech, Inc. Stromal gene signatures for diagnosis and use in immunotherapy
WO2017201449A1 (en) 2016-05-20 2017-11-23 Genentech, Inc. Protac antibody conjugates and methods of use
US20170368168A1 (en) 2016-05-27 2017-12-28 Agenus Inc. Anti-tim-3 antibodies and methods of use thereof
WO2017205741A1 (en) 2016-05-27 2017-11-30 Genentech, Inc. Bioanalytical method for the characterization of site-specific antibody-drug conjugates
WO2017210617A3 (en) 2016-06-02 2018-02-08 Porter, David, L. Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
WO2017208210A1 (en) 2016-06-03 2017-12-07 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
US20170348422A1 (en) 2016-06-06 2017-12-07 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
US20170355774A1 (en) 2016-06-10 2017-12-14 Regeneron Pharmaceuticals, Inc. Anti-gitr antibodies and uses thereof
GB201610198D0 (en) 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
WO2018045110A1 (en) 2016-08-30 2018-03-08 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
WO2017218698A1 (en) 2016-06-15 2017-12-21 Sutro Biopharma, Inc. Antibodies with engineered ch2 domains, compositions thereof and methods of using the same
WO2017218891A1 (en) 2016-06-17 2017-12-21 Life Technologies Corporation Site-specific crosslinking of antibodies
WO2017223405A1 (en) 2016-06-24 2017-12-28 Genentech, Inc. Anti-polyubiquitin multispecific antibodies
WO2018007314A1 (en) 2016-07-04 2018-01-11 F. Hoffmann-La Roche Ag Novel antibody format
WO2018007979A1 (en) 2016-07-06 2018-01-11 Prothena Biosciences Limited Assay for detecting total and s129 phosphorylated alpha-synuclein
WO2018007999A1 (en) 2016-07-08 2018-01-11 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
WO2018009732A1 (en) 2016-07-08 2018-01-11 Regeneron Pharmaceuticals, Inc. Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension
WO2018011073A1 (en) 2016-07-12 2018-01-18 H. Lundbeck A/S Antibodies specific for hyperphosphorylated tau and methods of use thereof
WO2018011421A1 (en) 2016-07-14 2018-01-18 Genmab A/S Multispecific antibodies against cd40 and cd137
WO2018013917A1 (en) 2016-07-15 2018-01-18 Takeda Pharmaceutical Company Limited Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies
WO2018013918A3 (en) 2016-07-15 2018-02-22 Novartis Ag Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
WO2018017673A1 (en) 2016-07-20 2018-01-25 Stcube, Inc. Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated pd-l1
WO2018015573A3 (en) 2016-07-22 2018-03-01 Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) Trem2 cleavage modulators and uses thereof
CN107446045A (en) 2016-07-22 2017-12-08 北京天广实生物技术股份有限公司 Antibody for resisting human epidermal growth factor receptor 2 (HER2), as well as medical composition and use of antibody
WO2018022479A1 (en) 2016-07-25 2018-02-01 Biogen Ma Inc. Anti-hspa5 (grp78) antibodies and uses thereof
WO2018022945A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd112 variant immunomodulatory proteins and uses thereof
WO2018023025A1 (en) 2016-07-28 2018-02-01 Novartis Ag Combination therapies of chimeric antigen receptors adn pd-1 inhibitors
WO2018022946A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd155 variant immunomodulatory proteins and uses thereof
WO2018023100A3 (en) 2016-07-29 2018-03-08 Juno Therapeutics, Inc. Anti-idiotypic antibodies against anti-cd19 antibodies
NL2017267B1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
WO2018026819A3 (en) 2016-08-01 2018-03-08 Novartis Ag Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
WO2018026953A1 (en) 2016-08-02 2018-02-08 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
WO2018027204A1 (en) 2016-08-05 2018-02-08 Genentech, Inc. Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
WO2018029124A1 (en) 2016-08-08 2018-02-15 F. Hoffmann-La Roche Ag Therapeutic and diagnostic methods for cancer
WO2018031662A1 (en) 2016-08-11 2018-02-15 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
WO2018031258A1 (en) 2016-08-12 2018-02-15 Janssen Biotech, Inc. Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
WO2018035025A1 (en) 2016-08-15 2018-02-22 Genentech, Inc. Chromatography method for quantifying a non-ionic surfactant in a composition comprising the non-ionic surfactant and a polypeptide
EP3347379A1 (en) 2016-08-17 2018-07-18 Compugen Ltd. Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
WO2018050878A1 (en) 2016-09-19 2018-03-22 F. Hoffmann-La Roche Ag Complement factor based affinity chromatography
US20180112001A1 (en) 2016-09-23 2018-04-26 Regeneron Pharmaceuticals, Inc. Anti-MUC16 Antibodies, Antibody-Drug Conjugates, and Bispecific Antigen-Binding Molecules that Bind MUC16 and CD3, and Uses Thereof
WO2018058001A1 (en) 2016-09-23 2018-03-29 Regeneron Pharmaceuticals, Inc. Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
WO2018057849A1 (en) 2016-09-23 2018-03-29 Genentech, Inc. Uses of il-13 antagonists for treating atopic dermatitis
US20180118849A1 (en) 2016-09-30 2018-05-03 Hoffmann-La Roche Inc. Bispecific t cell activating antigen binding molecules
WO2018065501A1 (en) 2016-10-05 2018-04-12 F. Hoffmann-La Roche Ag Methods for preparing antibody drug conjugates
US20180125892A1 (en) 2016-10-07 2018-05-10 Barbara Brannetti Treatment of cancer using chimeric antigen receptors
WO2018067993A1 (en) 2016-10-07 2018-04-12 TCR2 Therapeutics Inc. Compositions and methods for t-cell receptors reprogramming using fusion proteins
WO2018071597A1 (en) 2016-10-12 2018-04-19 Sutro Biopharma, Inc. Anti-folate receptor antibodies, compositions comprising anti-folate receptor antibodies and methods of making and using anti-folate receptor antibodies
WO2018071822A3 (en) 2016-10-13 2018-05-24 Massachusetts Institute Of Technology Antibodies that bind zika virus envelope protein and uses thereof
WO2018071919A1 (en) 2016-10-14 2018-04-19 Xencor, Inc. IL15/IL15Rα HETERODIMERIC FC-FUSION PROTEINS
US20180105588A1 (en) 2016-10-14 2018-04-19 Boehringer Ingelheim International Gmbh Methods of treating diseases
US20180118811A1 (en) 2016-10-19 2018-05-03 Invenra Inc. Antibody constructs
US20180127487A1 (en) 2016-10-20 2018-05-10 Sanofi Anti-chikv antibodies and uses thereof
WO2018077926A1 (en) 2016-10-25 2018-05-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Monoclonal antibodies binding to the cd160 transmembrane isoform
WO2018081648A2 (en) 2016-10-29 2018-05-03 Genentech, Inc. Anti-mic antibidies and methods of use
US20180118829A1 (en) 2016-11-02 2018-05-03 Jounce Therapeutics, Inc. Antibodies to pd-1 and uses thereof
WO2018089373A9 (en) 2016-11-08 2018-07-12 Regeneron Pharmaceuticals, Inc. Steroids and protein-conjugates thereof
US20180194833A1 (en) 2016-11-15 2018-07-12 H. Lundbeck A/S Agents, uses and methods for the treatment of synucleinopathy
US20180134798A1 (en) 2016-11-15 2018-05-17 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
WO2018094300A1 (en) 2016-11-19 2018-05-24 Potenza Therapeutics, Inc. Anti-gitr antigen-binding proteins and methods of use thereof
WO2018091724A1 (en) 2016-11-21 2018-05-24 Cureab Gmbh Anti-gp73 antibodies and immunoconjugates
WO2018098365A3 (en) 2016-11-22 2018-07-12 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
US20180185504A1 (en) 2016-11-29 2018-07-05 Regeneron Pharmaceuticals, Inc. Methods of treating prlr positive breast cancer
WO2018109058A1 (en) 2016-12-16 2018-06-21 H. Lundbeck A/S Agents, uses and methods
WO2018115960A1 (en) 2016-12-19 2018-06-28 Mosaic Biomedicals, S.L. Antibodies against lif and uses thereof
WO2018114754A1 (en) 2016-12-19 2018-06-28 F. Hoffmann-La Roche Ag Combination therapy with targeted 4-1bb (cd137) agonists
WO2018114728A1 (en) 2016-12-20 2018-06-28 F. Hoffmann-La Roche Ag Combination therapy with a bispecific anti-ang2/vegf antibody and a bispecific anti-her2 antibody
WO2018114748A1 (en) 2016-12-20 2018-06-28 F. Hoffmann-La Roche Ag Combination therapy of anti-cd20/anti-cd3 bispecific antibodies and 4-1bb (cd137) agonists
WO2018114877A1 (en) 2016-12-21 2018-06-28 F. Hoffmann-La Roche Ag In vitro glycoengineering of antibodies
WO2018114878A1 (en) 2016-12-21 2018-06-28 F. Hoffmann-La Roche Ag Re-use of enzymes in in vitro glycoengineering of antibodies
WO2018119215A9 (en) 2016-12-21 2018-11-22 Teneobio, Inc. Anti-bcma heavy chain-only antibodies
WO2018114879A1 (en) 2016-12-21 2018-06-28 F. Hoffmann-La Roche Ag Method for in vitro glycoengineering of antibodies
US20180179273A1 (en) 2016-12-22 2018-06-28 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
WO2018127473A1 (en) 2017-01-03 2018-07-12 F. Hoffmann-La Roche Ag Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9
WO2018127519A1 (en) 2017-01-04 2018-07-12 H. Lundbeck A/S Antibodies specific for hyperphosphorylated tau for the treatment of ocular diseases
WO2018143266A1 (en) 2017-01-31 2018-08-09 Chugai Seiyaku Kabushiki Kaisha A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
WO2018156785A1 (en) 2017-02-22 2018-08-30 Sutro Biopharma, Inc. Pd-1/tim-3 bi-specific antibodies, compositions thereof, and methods of making and using the same
JP2018139530A (en) 2017-02-27 2018-09-13 帝人ファーマ株式会社 Humanized antibodies and methods producing the same for dementia treatment or prevention, as well as dementia therapeutic agents or prophylactic agents using the same
WO2018183182A1 (en) 2017-03-27 2018-10-04 Celgene Corporation Methods and compositions for reduction of immunogenicity
US20180273627A1 (en) 2017-03-27 2018-09-27 Boehringer Ingelheim International Gmbh Anti il-36r antibodies combination therapy
WO2018185045A1 (en) 2017-04-04 2018-10-11 F. Hoffmann-La Roche Ag Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap
WO2018185043A1 (en) 2017-04-05 2018-10-11 F. Hoffmann-La Roche Ag Bispecific antibodies specifically binding to pd1 and lag3
WO2018208625A1 (en) 2017-05-06 2018-11-15 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with aplnr antagonists and vegf inhibitors
EP3401328A1 (en) 2017-05-10 2018-11-14 Bayer Pharma Aktiengesellschaft One step antibody humanization by golden gate based germline framework region shuffling
WO2018211517A1 (en) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6054561A (en) 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US4753894A (en) 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
US5169774A (en) 1984-02-08 1992-12-08 Cetus Oncology Corporation Monoclonal anti-human breast cancer antibodies
US4845198A (en) 1984-05-21 1989-07-04 Immunex Corporation Hybridoma antibody which binds IL-2 receptor
WO1987002671A1 (en) 1985-11-01 1987-05-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB2188941B (en) 1986-04-14 1990-06-06 Bayer Ag Monoclonal antibodies recognizing human interleukin-2-receptor
US4968603A (en) * 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
EP0623679B1 (en) 1987-05-21 2003-06-25 Micromet AG Targeted multifunctional proteins
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
JP2646007B2 (en) 1988-01-30 1997-08-25 財団法人 化学及血清療法研究所 Gene fragment and anti-hiv chimeric antibodies and preparation thereof are expressed using these encoding an anti-hiv antibody variable region
WO1989009622A1 (en) 1988-04-15 1989-10-19 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
ES2070172T3 (en) 1988-04-16 1995-06-01 Celltech Ltd A process for producing proteins by recombinant DNA.
EP0365209A3 (en) 1988-10-17 1990-07-25 Becton Dickinson and Company Anti-leu 3a amino acid sequence
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69028684T2 (en) 1989-06-02 1997-05-22 Univ Johns Hopkins Med Against the beta-chain of the leukocyte adhesion receptor monoclonal antibodies directed, processes for their preparation and their use
CA2018248A1 (en) 1989-06-07 1990-12-07 Clyde W. Shearman Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use
GB8925590D0 (en) 1989-11-13 1990-01-04 Central Blood Lab Authority Monoclonal antibodies
US5994510A (en) 1990-12-21 1999-11-30 Celltech Therapeutics Limited Recombinant antibodies specific for TNFα
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP0438310A1 (en) 1990-01-19 1991-07-24 Merck &amp; Co., Inc. Method for producing recombinant immunoglobuline
EP0438312A3 (en) 1990-01-19 1992-07-01 Merck & Co. Inc. Recombinant human anti-cd18 antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
GB9019553D0 (en) 1990-09-07 1990-10-24 Unilever Plc Specific binding agents
GB9019812D0 (en) 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
GB9020282D0 (en) 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
KR100240308B1 (en) 1991-03-06 2000-01-15 플레믹 크리스티안 Humanized and chimeric monoclonal antibodies
GB9105245D0 (en) 1991-03-12 1991-04-24 Lynxvale Ltd Binding molecules
GB9109645D0 (en) 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
EP0519596B1 (en) * 1991-05-17 2005-02-23 Merck &amp; Co., Inc. A method for reducing the immunogenicity of antibody variable domains
LU91067I2 (en) * 1991-06-14 2004-04-02 Genentech Inc Trastuzumab and its variants and derivatives chemical immuno including immotoxines
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
DE69332930T2 (en) 1992-11-16 2004-02-26 Cancer Research Fund Of Contra Costa, Walnut Creek Peptides with broad specificity of neoplastic

Also Published As

Publication number Publication date Type
LU91067I2 (en) 2004-04-02 grant
JPH06508267A (en) 1994-09-22 application
DE69233254T2 (en) 2004-09-16 grant
NL300145I1 (en) 2004-06-01 grant
US6639055B1 (en) 2003-10-28 grant
EP0590058A1 (en) 1994-04-06 application
JP4124480B2 (en) 2008-07-23 grant
JP2008291036A (en) 2008-12-04 application
CA2103059C (en) 2005-03-22 grant
WO1992022653A1 (en) 1992-12-23 application
EP1400536A1 (en) 2004-03-24 application
JP4836147B2 (en) 2011-12-14 grant
ES2206447T3 (en) 2004-05-16 grant
JP2006083180A (en) 2006-03-30 application
DE122004000008I1 (en) 2005-06-09 grant
EP0940468A1 (en) 1999-09-08 application
EP0590058B1 (en) 2003-11-26 grant
US6407213B1 (en) 2002-06-18 grant
LU91067A9 (en) application
US6719971B1 (en) 2004-04-13 grant
DK0590058T3 (en) 2004-03-29 grant
DE69233254D1 (en) 2004-01-08 grant
JP2005000169A (en) 2005-01-06 application
US5821337A (en) 1998-10-13 grant

Similar Documents

Publication Publication Date Title
JPS6336794A (en) Monoclonal antibody, hybridoma producing the same and method for detecting and imaging kidney cell carcinoma using the same
CA2012264A1 (en) Anti-human sperm antibody and its production and use
JPS6463392A (en) Monoclonal antibody against specific antigen for human immunodeficiency virus

Legal Events

Date Code Title Description
EEER Examination request
FZDC Correction of dead application (reinstatement)
MKEX Expiry